[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3829
1. Cosan DT, Bayram B, Soyocak A, Basaran A, Gunes HV, Degirmenci I, Musmul A: Role of phenolic compounds in nitric oxide synthase activity in colon and breast adenocarcinoma. Cancer Biother Radiopharm; 2010 Oct;25(5):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of phenolic compounds in nitric oxide synthase activity in colon and breast adenocarcinoma.
  • Cancer chemopreventive agents are designed to reduce the incidence of tumorigenesis by intervening at one or more stages of carcinogenesis.
  • This study aimed to determine the effects of resveratrol (RES) and tannic acid (TA), which are chemopreventive agents, on the nitric oxide synthase (NOS) levels that are effective for development of cancer in colon and breast cancer cell lines.
  • The CaCo-2 (human colon carcinoma cell line) and MCF-7 (Michigan Cancer Foundation-7; human breast adenocarcinoma cell line) cells were grown in the laboratory.
  • Nitric Oxide Synthase Assay Kit was used to determine the NOS enzyme activity of CaCo-2 and MCF-7.
  • Results suggest that the phenolic compounds RES and TA have different effects on NOS enzyme activity of the colon and breast cancer cells.
  • [MeSH-major] Adenocarcinoma / enzymology. Anticarcinogenic Agents / pharmacology. Breast Neoplasms / enzymology. Colonic Neoplasms / enzymology. Nitric Oxide Synthase / metabolism. Phenols / pharmacology. Stilbenes / pharmacology. Tannins / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. RESVERATROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20874429.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Phenols; 0 / Stilbenes; 0 / Tannins; EC 1.14.13.39 / Nitric Oxide Synthase; Q369O8926L / resveratrol
  •  go-up   go-down


2. Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, Fabbro D, Wartmann M, Folkers G, Pruschy M: Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res; 2005 Feb 15;11(4):1588-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
  • Here we have investigated the effect of combined treatment with ionizing radiation and patupilone or paclitaxel in the P-glycoprotein-overexpressing, p53-mutated human colon adenocarcinoma cell line SW480 and in murine, genetically defined E1A/ras-transformed paclitaxel-sensitive embryo fibroblasts.

  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746064.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epothilones; 0 / P-Glycoproteins; 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel; UEC0H0URSE / epothilone B
  •  go-up   go-down


3. Luca T, Privitera G, Lo Monaco M, Prezzavento C, Castorina S: Validation study of a cell culture model of colorectal cancer. Ital J Anat Embryol; 2007 Apr-Jun;112(2):81-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation study of a cell culture model of colorectal cancer.
  • Colorectal cancer is a significant cause of morbidity and mortality in Western populations.
  • Due to the fact that epithelial cells of colon have an important role in the pathophysiology of cancer, we set up a mechanical method combined with an enzymatic digestion of surgical resections derived from our Clinical Centre to obtain tumoral colon epithelium cell cultures.
  • This validated model of primary epithelial cells from colon cancer will be used to understand the biological and pathological features of human tumoral colonic cells.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Colonic Neoplasms / pathology. Colorectal Neoplasms / pathology. Epithelial Cells / pathology. Models, Biological

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687873.001).
  • [ISSN] 1122-6714
  • [Journal-full-title] Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia
  • [ISO-abbreviation] Ital J Anat Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Glycosaminoglycans; 0 / Homeodomain Proteins; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; P4448TJR7J / Alcian Blue
  •  go-up   go-down


Advertisement
4. Rafailidis SF, Ballas KD, Symeonidis N, Pavlidis TE, Emoniotou E, Psarras K, Pantzaki A, Marakis GN, Sakadamis AK: Pelvic malakoplakia simulating recurrence of rectal adenocarcinoma: report of a case. Tech Coloproctol; 2009 Mar;13(1):79-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic malakoplakia simulating recurrence of rectal adenocarcinoma: report of a case.
  • We report herein the case of a 66-year-old woman who, having undergone lower anterior resection for rectal adenocarcinoma 3 and a half years ago, presented with urinary frequency and dull abdominal pain.
  • [MeSH-major] Adenocarcinoma / surgery. Malacoplakia / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pelvis / pathology. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Malakoplakia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1988 Jun;12(6):672-5 [3417248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1025-9 [7607922.001]
  • [Cites] J Urol. 1995 Aug;154(2 Pt 1):523-4 [7609124.001]
  • [Cites] J Urol. 1981 Feb;125(2):139-46 [7009885.001]
  • [Cites] Ann Urol (Paris). 2002 Dec;36(6):388-91 [12611142.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1371-5 [11584219.001]
  • [Cites] Int J Gynecol Pathol. 2001 Oct;20(4):403-6 [11603228.001]
  • [Cites] Changgeng Yi Xue Za Zhi. 1998 Sep;21(3):318-22 [9849014.001]
  • [Cites] J Pathol. 1983 Aug;140(4):275-330 [6308195.001]
  • [Cites] Arch Intern Med. 1996 Mar 11;156(5):577-83 [8604965.001]
  • (PMID = 18679567.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Shrivastav A, Singh NK, Tripathi P, George T, Dimmock JR, Sharma RK: Copper(II) and manganese(III) complexes of N'-[(2-hydroxy phenyl) carbonothioyl] pyridine-2-carbohydrazide: novel therapeutic agents for cancer. Biochimie; 2006 Sep;88(9):1209-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Copper(II) and manganese(III) complexes of N'-[(2-hydroxy phenyl) carbonothioyl] pyridine-2-carbohydrazide: novel therapeutic agents for cancer.
  • We have shown earlier increased NMT activity in the early stages of colon cancer.
  • These Cu(II) and Mn(III) complexes showed cytotoxicity against the colon cancer cell line HT29.
  • These metal complexes may prove to be novel therapeutic agents for cancer targeting NMT.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1433-8 [498145.001]
  • [Cites] Science. 1985 Jan 25;227(4685):427-9 [3917576.001]
  • [Cites] Cancer. 1985 May 15;55(10):2303-l6 [3886121.001]
  • [Cites] J Biol Chem. 1985 Nov 5;260(25):13710-8 [4055754.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(8):2251-5 [2436227.001]
  • [Cites] Anal Biochem. 1991 Dec;199(2):149-53 [1725948.001]
  • [Cites] Biochem J. 1993 Apr 15;291 ( Pt 2):635-9 [8484742.001]
  • [Cites] CA Cancer J Clin. 1994 Jan-Feb;44(1):7-26 [8281473.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1571-3 [7563194.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1630-5 [7563206.001]
  • [Cites] Protein Expr Purif. 1996 Jun;7(4):431-7 [8776763.001]
  • [Cites] Cell Signal. 1997 Jan;9(1):15-35 [9067626.001]
  • [Cites] Exp Cell Res. 1997 Aug 25;235(1):145-54 [9281363.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:513-609 [9442882.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):6595-8 [9506952.001]
  • [Cites] Biochemistry. 1998 Oct 20;37(42):14928-36 [9778369.001]
  • [Cites] Adv Cancer Res. 1999;76:61-119 [10218099.001]
  • [Cites] Biochim Biophys Acta. 1999 Aug 12;1451(1):1-16 [10446384.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18990-5 [15753093.001]
  • [Cites] Cell Biochem Biophys. 2005;43(1):189-202 [16043893.001]
  • [Cites] Mol Cancer Res. 2005 Aug;3(8):463-76 [16123142.001]
  • [Cites] Semin Oncol. 1999 Dec;26(6):647-62 [10606258.001]
  • [Cites] Mol Cell Biochem. 2000 Jan;204(1-2):135-55 [10718634.001]
  • [Cites] Cancer. 2000 May 1;88(9):1992-9 [10813869.001]
  • [Cites] Drugs. 2000;59 Suppl 4:19-27 [10864227.001]
  • [Cites] Exp Cell Res. 2001 Jan 15;262(2):134-44 [11139338.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):39501-4 [11527981.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8534-9 [11731439.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Jun;10(6):1011-9 [11772231.001]
  • [Cites] Bioorg Med Chem. 2002 Apr;10(4):887-95 [11836095.001]
  • [Cites] Bioorg Med Chem. 2002 Aug;10(8):2693-704 [12057658.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Aug;11(8):1117-25 [12150705.001]
  • [Cites] Biometals. 2003 Jun;16(2):311-20 [12572689.001]
  • [Cites] Curr Pharm Des. 2003;9(25):2078-89 [14529417.001]
  • [Cites] J Enzyme Inhib Med Chem. 2003 Aug;18(4):313-24 [14567546.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7975-8 [14633729.001]
  • [Cites] Int J Mol Med. 2004 Apr;13(4):557-63 [15010856.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Apr;309(1):340-7 [14724220.001]
  • [Cites] Biochem Cell Biol. 2004 Apr;82(2):263-74 [15060621.001]
  • [Cites] J Cell Biochem. 2004 Jun 1;92(3):573-8 [15156568.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):470-80 [15170449.001]
  • [Cites] Naturwissenschaften. 1973 Sep;60(9):399-406 [4203933.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Adv Exp Med Biol. 1977;91:129-50 [343531.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • (PMID = 16600465.001).
  • [ISSN] 0300-9084
  • [Journal-full-title] Biochimie
  • [ISO-abbreviation] Biochimie
  • [Language] ENG
  • [Grant] None / None / / 53171; Canada / Canadian Institutes of Health Research / / 53171
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydrazines; 0 / Ligands; 0 / N'-((2-hydroxyphenyl)carbonothioyl)pyridine-2-carbohydrazide; 0 / Organometallic Compounds; 0 / Sulfhydryl Compounds; 42Z2K6ZL8P / Manganese; 789U1901C5 / Copper; EC 2.3.- / Acyltransferases; EC 2.3.1.97 / glycylpeptide N-tetradecanoyltransferase
  • [Other-IDs] NLM/ CAMS2158; NLM/ PMC3310915
  •  go-up   go-down


6. Colvin M, Delis A, Bracamonte E, Villar H, Leon LR Jr: Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal. World J Gastroenterol; 2009 Jul 28;15(28):3560-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal.
  • In particular, adenomas and adenocarcinomas are distinctly rare entities in this region.
  • We describe an infiltrating, well-differentiated adenocarcinoma arising in a villous adenoma from the distal anal canal, in an otherwise healthy patient at low risk for gastrointestinal malignancy.
  • Microscopic evaluation revealed an infiltrating well-differentiated adenocarcinoma, arising from a villous adenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Anal Canal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2000 Aug;66(8):789-92 [10966042.001]
  • [Cites] Colorectal Dis. 2008 Jul;10(6):621-3 [17949443.001]
  • [Cites] Histopathology. 2002 Mar;40(3):302-4 [11895502.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1320-4 [14530668.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):249-62 [15137955.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1780-1 [16586552.001]
  • [Cites] Colorectal Dis. 2006 May;8(4):296-301 [16630233.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):576-8 [17101482.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7304-8 [17143945.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1977-9 [17212165.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] Surg Today. 2007;37(7):596-9 [17593481.001]
  • [Cites] Tech Coloproctol. 2007 Dec;11(4):340-2 [18060528.001]
  • [Cites] J Am Osteopath Assoc. 2001 Aug;101(8):450-3 [11526879.001]
  • (PMID = 19630115.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2715986
  •  go-up   go-down


7. Hwang HJ, Song KH, Youn YH, Kwon JE, Kim H, Chung JB, Lee YC: A case of more abundant and dysplastic adenomas in the interposed colon than in the native colon. Yonsei Med J; 2007 Dec 31;48(6):1075-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of more abundant and dysplastic adenomas in the interposed colon than in the native colon.
  • We report a 60-year-old woman with intramucosal adenocarcinoma arising in the interposed colon, 40 years after the esophageal reconstruction for lye induced esophageal stricture.
  • Although synchronous adenomas were also found in the native colon where the graft was taken, the number of adenomas was greater in the interposed colon and more dysplastic, even progressed to adenocarcinoma, than that of the native colon.
  • The microsatellite instability-testing performed in the intramucosal carcinoma from interposed colon showed absence of microsatellite instability.
  • Changing of location and functional demand of colonic segment, and the exposure to different intraluminal contents might have facilitated the adenoma- carcinoma transformation in the interposed colon.
  • [MeSH-major] Adenoma / pathology. Colon / pathology. Colonic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Disease Progression. Esophagoplasty / adverse effects. Esophagoplasty / methods. Female. Humans. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):852-4 [10570353.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):797-9 [8847026.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):209-10 [12867603.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):536-41; discussion 541-2 [15051003.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):748-9 [15143907.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] Rom J Gastroenterol. 2004 Sep;13(3):187-93 [15470530.001]
  • [Cites] Ann Surg. 1968 Jan;167(1):98-100 [5635190.001]
  • [Cites] Gut. 1967 Dec;8(6):569-73 [6079810.001]
  • [Cites] Lancet. 1978 Feb 4;1(8058):285 [74716.001]
  • [Cites] AJR Am J Roentgenol. 1984 Apr;142(4):703-8 [6608225.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):681-90 [4005819.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2304-7 [3440237.001]
  • [Cites] Gut. 1989 Jun;30(6):880-1 [2753412.001]
  • [Cites] Eur J Surg. 1991 Mar;157(3):189-92 [1678628.001]
  • [Cites] Aust N Z J Surg. 1992 Feb;62(2):158-60 [1586307.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):859-61 [1640334.001]
  • [Cites] J Laryngol Otol. 1994 Jan;108(1):80-3 [8133180.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):555-8 [10789758.001]
  • (PMID = 18159607.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628170
  •  go-up   go-down


8. Lohsiriwat V, Lohsiriwat D, Boonnuch W, Chinswangwatanakul V, Akaraviputh T, Lert-Akayamanee N: Pre-operative hypoalbuminemia is a major risk factor for postoperative complications following rectal cancer surgery. World J Gastroenterol; 2008 Feb 28;14(8):1248-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative hypoalbuminemia is a major risk factor for postoperative complications following rectal cancer surgery.
  • AIM: To determine the relationship between pre-operative hypoalbuminemia and the development of complications following rectal cancer surgery, as well as postoperative bowel function and hospital stay.
  • METHODS: The medical records of 244 patients undergoing elective oncological resection for rectal adenocarcinoma at Siriraj Hospital during 2003 and 2006 were reviewed.
  • CONCLUSION: Pre-operative hypoalbuminemia is an independent risk factor for postoperative complications following rectal cancer surgery.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Healthc Qual. 2000 Mar-Apr;22(2):4-7; quiz 7, 15 [10847865.001]
  • [Cites] J Gastrointest Surg. 2007 Oct;11(10):1355-60 [17682826.001]
  • [Cites] Ann Ital Chir. 2000 Jul-Aug;71(4):433-40 [11109667.001]
  • [Cites] Surgery. 2001 May;129(5):617-25 [11331454.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2941-7 [11712791.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2003 Jan-Feb;27(1):1-9 [12549591.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):653-60 [12792443.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):91-8 [15112251.001]
  • [Cites] J Am Coll Nutr. 2004 Jun;23(3):227-32 [15190047.001]
  • [Cites] J Am Diet Assoc. 2004 Aug;104(8):1258-64 [15281044.001]
  • [Cites] Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:61-6 [15357853.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):719-26; discussion 726-7 [15383799.001]
  • [Cites] Ann Surg. 1974 Nov;180(5):765-72 [4418508.001]
  • [Cites] Br J Surg. 1982 Jun;69(6):308-10 [6805546.001]
  • [Cites] Cell Immunol. 1992 Feb;139(2):493-504 [1310262.001]
  • [Cites] Nutrition. 1993 Mar-Apr;9(2):140-5 [8485326.001]
  • [Cites] Am Surg. 1993 Nov;59(11):758-63 [8239200.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Aug;10(4):791-800 [8811301.001]
  • [Cites] Crit Care Med. 1997 Feb;25(2):249-52 [9034259.001]
  • [Cites] CA Cancer J Clin. 1998 Mar-Apr;48(2):69-80 [9522822.001]
  • [Cites] Anaesthesia. 1998 Aug;53(8):789-803 [9797524.001]
  • [Cites] Arch Surg. 1999 Jan;134(1):36-42 [9927128.001]
  • [Cites] Nutr Rev. 2004 Nov;62(11):443-7 [15622717.001]
  • [Cites] Arch Surg. 2005 Mar;140(3):278-83, discussion 284 [15781793.001]
  • [Cites] Eur J Oncol Nurs. 2005;9 Suppl 2:S51-63 [16437758.001]
  • [Cites] World J Surg. 2006 Mar;30(3):378-90 [16479353.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1382-91 [16850151.001]
  • [Cites] Asia Pac J Clin Nutr. 2007;16(2):213-7 [17468075.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):83-91 [10813129.001]
  • (PMID = 18300352.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2690674
  •  go-up   go-down


9. Wilde BK, Senger JL, Kanthan R: Gastrointestinal schwannoma: an unusual colonic lesion mimicking adenocarcinoma. Can J Gastroenterol; 2010 Apr;24(4):233-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal schwannoma: an unusual colonic lesion mimicking adenocarcinoma.
  • Gastrointestinal schwannoma is a rare, benign pathological entity that can mimic colonic adenocarcinoma and cause diagnostic dilemmas for treatment.
  • A case of a 68-year-old woman with colonic adenocarcinoma who was discovered to have an incidental synchronous bowel lesion that proved to be a gastrointestinal schwannoma and not a synchronous adenocarcinoma is described.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Neurilemmoma / diagnosis

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2001;31(9):833-8 [11686568.001]
  • [Cites] Dis Esophagus. 2009;22(4):E6-E10 [19473209.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1361-71 [13679444.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1992 Apr;73(4):469-71 [1374171.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):59-70 [7802139.001]
  • [Cites] J Gastroenterol. 1998 Dec;33(6):872-5 [9853563.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):431-6 [10199472.001]
  • [Cites] World J Gastroenterol. 2005 Aug 28;11(32):5079-81 [16124072.001]
  • [Cites] Histopathology. 2006 Apr;48(5):536-45 [16623779.001]
  • [Cites] Adv Anat Pathol. 2007 May;14(3):178-88 [17452814.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):717-20 [17622556.001]
  • [Cites] World J Gastroenterol. 2007 Nov 7;13(41):5521-4 [17907300.001]
  • [Cites] Ann Diagn Pathol. 2008 Apr;12(2):146-52 [18325478.001]
  • [Cites] Clin Radiol. 2008 May;63(5):536-42 [18374717.001]
  • [Cites] Yonsei Med J. 2008 Dec 31;49(6):1052-4 [19108033.001]
  • [Cites] APMIS. 2009 Feb;117(2):73-86 [19239429.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2287-9 [19437573.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • (PMID = 20431810.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2864617
  •  go-up   go-down


10. Acquaviva F, De Biase I, Nezi L, Ruggiero G, Tatangelo F, Pisano C, Monticelli A, Garbi C, Acquaviva AM, Cocozza S: Extra-mitochondrial localisation of frataxin and its association with IscU1 during enterocyte-like differentiation of the human colon adenocarcinoma cell line Caco-2. J Cell Sci; 2005 Sep 1;118(Pt 17):3917-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-mitochondrial localisation of frataxin and its association with IscU1 during enterocyte-like differentiation of the human colon adenocarcinoma cell line Caco-2.
  • We used the human colon adenocarcinoma cell line Caco-2, as it is considered a good model for intestinal epithelial differentiation and the study of intestinal iron metabolism.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091420.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ISCU protein, human; 0 / Iron-Binding Proteins; 0 / Iron-Sulfur Proteins; 0 / Isoenzymes; 0 / frataxin; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


11. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Different patterns of lymphatic spread of sigmoid, rectosigmoid, and rectal cancers. Ann Surg Oncol; 2008 Dec;15(12):3478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We tried to evaluate the clinicopathological characteristics of rectosigmoid cancer compared with those of sigmoid and rectal cancer.
  • METHODS: We collected data on patients who underwent curative resections for sigmoid (399; SC group), rectosigmoid (175; RS group), and upper rectal cancer (453; RA group) between June 1996 and December 2007.
  • RESULTS: The mean distance from the anal verge was 12.5 cm for rectosigmoid cancer, 13 cm for sigmoid cancer, and 9.8 cm for rectal cancer.
  • CONCLUSION: Clinicopathological characteristics of rectosigmoid cancer were similar to those of sigmoid or rectal cancer.
  • For lymphatic spreads, it was different from sigmoid or rectal cancer and more frequently metastasized to pararectal nodes.
  • Oncologic results were slightly unfavorable to sigmoid colon, and showed data similar to those of rectal cancer.
  • Therefore, rectosigmoid cancer was a "real" classification of colorectal cancer with unique lymphatic spread.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Carcinoma, Signet Ring Cell / secondary. Lymph Nodes / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):346-7 [19841983.001]
  • (PMID = 18830668.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Li M, Li JY, Zhao AL, He JS, Zhou LX, Li YA, Gu J: Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1. Dis Colon Rectum; 2007 Nov;50(11):1887-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / nursing. Carcinoembryonic Antigen / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / mortality. Intracellular Signaling Peptides and Proteins / metabolism. Matrix Metalloproteinase 2 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882488.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Carcinoembryonic Antigen; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


13. Park ET, Oh HK, Gum JR Jr, Crawley SC, Kakar S, Engel J, Leow CC, Gao WQ, Kim YS: HATH1 expression in mucinous cancers of the colorectum and related lesions. Clin Cancer Res; 2006 Sep 15;12(18):5403-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Mucinous cancers and signet ring carcinomas are distinct classes of colon cancers characterized by their production of copious quantities of intestinal goblet cell mucin, MUC2.
  • Deletion of transcription factor HATH1 ablates the biogenesis of goblet cells in developing mouse intestine, and forced expression of HATH1 results in elevated expression of MUC2 in colon cancer cells.
  • EXPERIMENTAL DESIGN: Immunohistochemistry and confocal microscopy was used to examine HATH1 expression and subcellular distribution in normal colon and small intestine, mucinous cancers, signet ring carcinomas, and nonmucinous cancers and in precursor lesions, including hyperplastic polyps, serrated adenomas, tubular adenomas, and villous adenomas.
  • HATH1 was expressed in the nuclei of goblet cells and in the cytoplasm and nuclei of enteroendocrine cells of the colon.
  • In addition, the expression of HATH1 in hyperplastic polyps, serrated adenomas, and villous adenomas lends support to the hypothesis that these neoplasms are frequent precursors in mucinous cancer and signet ring carcinoma development.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Basic Helix-Loop-Helix Transcription Factors / metabolism. Colorectal Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000673.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATOH1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / MUC2 protein, human; 0 / Muc2 protein, mouse; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


14. Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F: Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res; 2005 Feb 1;11(3):1268-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in cancer cell growth.
  • Enhanced cyclooxygenase-2 (COX-2) expression has been linked to cancer cell proliferation, EGFR activation, VEGF secretion, and tumor-induced angiogenesis.
  • EXPERIMENTAL DESIGN: The antitumor activity in vitro and in vivo of ZD6474 and/or SC-236 was tested in human cancer cell lines with a functional EGFR autocrine pathway.
  • RESULTS: The combination of ZD6474 and SC-236 determined supra-additive growth inhibition in all cancer cell lines tested.
  • In nude mice bearing established human colon (GEO) or lung adenocarcinoma (A549) cancer xenografts and treated with ZD6474 and/or SC-236 for 3 weeks, a reversible tumor growth inhibition was seen with each agent, whereas a more prolonged growth inhibition that lasted for 3 to 5 weeks following the end of treatment resulted from the combination of the two agents.
  • CONCLUSIONS: This study provides a rationale for evaluating the simultaneous blockade of EGFR, COX-2, and VEGF signaling as cancer therapy in a clinical setting.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709198.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 0 / Cyclooxygenase Inhibitors; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


15. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet; 2008 Feb 16;371(9612):569-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.
  • We did a systematic review and meta-analysis to assess the strength of associations between BMI and different sites of cancer and to investigate differences in these associations between sex and ethnic groups.
  • METHODS: We did electronic searches on Medline and Embase (1966 to November 2007), and searched reports to identify prospective studies of incident cases of 20 cancer types.
  • We did random-effects meta-analyses and meta-regressions of study-specific incremental estimates to determine the risk of cancer associated with a 5 kg/m2 increase in BMI.
  • In men, a 5 kg/m2 increase in BMI was strongly associated with oesophageal adenocarcinoma (RR 1.52, p<0.0001) and with thyroid (1.33, p=0.02), colon (1.24, p<0.0001), and renal (1.24, p <0.0001) cancers.
  • In women, we recorded strong associations between a 5 kg/m2 increase in BMI and endometrial (1.59, p<0.0001), gallbladder (1.59, p=0.04), oesophageal adenocarcinoma (1.51, p<0.0001), and renal (1.34, p<0.0001) cancers.
  • We noted weaker positive associations (RR <1.20) between increased BMI and rectal cancer and malignant melanoma in men; postmenopausal breast, pancreatic, thyroid, and colon cancers in women; and leukaemia, multiple myeloma, and non-Hodgkin lymphoma in both sexes.
  • Associations were stronger in men than in women for colon (p<0.0001) cancer.
  • For some cancer types, associations differ between sexes and populations of different ethnic origins.
  • These epidemiological observations should inform the exploration of biological mechanisms that link obesity with cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2008 Feb 16;371(9612):536-7 [18280312.001]
  • [CommentIn] Cancer Epidemiol. 2016 Jun;42:1-8 [26946037.001]
  • (PMID = 18280327.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


16. Joseph UA, Barron BJ, Wan DQ: (18)F-Fluorodeoxy glucose (FDG) uptake in nontraumatic bilateral adrenal hemorrhage secondary to heparin-associated thrombocytopenia syndrome (HATS) - a case report. Clin Imaging; 2007 Mar-Apr;31(2):137-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our patient with breast and colon cancer developed gastrointestinal bleeding on heparin therapy, enlarged adrenals with heterogeneous attenuation consistent with hemorrhage and blood clots as seen on abdominal computed tomography scan, and as abnormal intense FDG activity in the bilateral adrenal glands on positron emission tomography scan.
  • [MeSH-minor] Adenocarcinoma / surgery. Adrenal Glands / metabolism. Adrenal Glands / radionuclide imaging. Aged. Colonic Neoplasms / surgery. Female. Humans. Positron-Emission Tomography. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320783.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9005-49-6 / Heparin
  •  go-up   go-down


17. Nishiyama N, Yamamoto S, Matsuoka N, Fujimoto H, Moriya Y: Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case. Surg Today; 2009;39(8):728-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case.
  • To our knowledge, there is no case report of the synchronous resection of colon and ureteral carcinomas by laparoscopy, because of the rareness of this combination and the technical difficulties involved.
  • We report a case of simultaneous descending colon and left ureteral carcinomas, both of which were judged to be relatively early stage carcinoma, which we resected successfully laparoscopically.
  • [MeSH-major] Carcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Nephrectomy / methods. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Colonoscopy. Humans. Laparoscopy. Male. Urography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Surg Today. 2007;37(11):1004-8 [17952536.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):364-70 [10955865.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2007 Aug;17 (4):283-6 [17710049.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10 Suppl):S30-6 [17106813.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Jun;14(3):179-81 [15245672.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Urol. 2005 Apr;173(4):1102-7 [15758710.001]
  • [Cites] Can J Surg. 2007 Feb;50(1):48-57 [17391617.001]
  • [Cites] Int J Colorectal Dis. 2006 Jan;21(1):92-3 [15668786.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Dec;13(6):382-6 [14712100.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Jun;16(3):297-300 [16796445.001]
  • [Cites] Urology. 2001 Jan;57(1):133-7 [11164158.001]
  • (PMID = 19639445.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L, Rao CV: Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res; 2006 Apr 15;66(8):4542-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
  • Preclinical and clinical studies have provided evidence that aspirin, celecoxib, (cyclooxygenase-2 inhibitor), and statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) inhibit colon carcinogenesis.
  • We assessed the efficacy of atorvastatin (lipitor), celecoxib, and aspirin, given individually at high dose levels and in combination at lower doses against azoxymethane-induced colon carcinogenesis, in male F 344 rats.
  • Rats were killed 42 weeks later, and colon tumors were processed histopathologically and analyzed for cell proliferation and apoptosis immunohistochemically.
  • Administration of these agents individually and in combination significantly suppressed the incidence and multiplicity of colon adenocarcinomas.
  • Low doses of these agents in combination inhibited colon carcinogenesis more effectively than when they were given individually at higher doses.
  • Inhibition of colon carcinogenesis by these agents is associated with the inhibition of cell proliferation and increase in apoptosis in colon tumors.
  • These observations are of clinical significance because this can pave the way for the use of combinations of these agents in small doses against colon cancer.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Aspirin / pharmacology. Colonic Neoplasms / prevention & control. Heptanoic Acids / pharmacology. Pyrazoles / pharmacology. Pyrroles / pharmacology. Sulfonamides / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618783.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01-CA-37663; United States / NCI NIH HHS / CA / 1R01-CA-94962; United States / NCI NIH HHS / CA / CA-17613; United States / NCI NIH HHS / CN / N01-CN-43308
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Heptanoic Acids; 0 / Pyrazoles; 0 / Pyrroles; 0 / Sulfonamides; 48A5M73Z4Q / Atorvastatin Calcium; JCX84Q7J1L / Celecoxib; MO0N1J0SEN / Azoxymethane; R16CO5Y76E / Aspirin
  •  go-up   go-down


19. Liu W, Liu Y, Zhu J, Wright E, Ding I, Rodgers GP: Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res; 2008 Feb 15;14(4):1041-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma.
  • The purpose of this study was to examine hGC-1 expression in colon carcinoma and explore the relationship between hGC-1 expression and the clinicopathologic features of patients with colon cancer.
  • EXPERIMENTAL DESIGN: The expression of hGC-1 in colon adenocarcinoma tissues was examined by dot-blot analysis, in situ hybridization, and immunohistochemistry.
  • To further investigate the involvement of hGC-1 in colon cancer progression, human colon carcinoma (HT-29) cells overexpressing hGC-1 were established and cell proliferation, adhesion, and migration were studied.
  • RESULTS: Compared with normal colon mucosa, the up-regulation of hGC-1 was more frequently detected in more differentiated colon cancers, whereas down-regulation or no expression was associated with poorly differentiated colon cancers.
  • CONCLUSION: Our findings indicate that hGC-1 is involved in colon cancer adhesion and metastasis, and that hGC-1 may be a useful marker for tumor differentiation and progression of human colon carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Granulocyte Colony-Stimulating Factor / biosynthesis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281536.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


20. Mizoshita T, Tsukamoto T, Inada KI, Hirano N, Tajika M, Nakamura T, Ban H, Tatematsu M: Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon. Histol Histopathol; 2007 03;22(3):251-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon.
  • METHODS AND RESULTS: We examined the correlation between gastric and intestinal phenotypic expression in 91 primary early carcinomas of the colon.
  • Intramucosal de novo carcinomas (flat type carcinomas without adenomatous components) exhibited a greater decrease of MUC2 than intramucosal lesions with adenomatous components.
  • CONCLUSIONS: Our data suggest that the reduction of MUC2 expression may be associated with the occurrence and progression of colorectal carcinomas in both adenoma-carcinoma sequence pathway and de novo carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Colorectal Neoplasms / metabolism. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163399.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Microfilament Proteins; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; 0 / villin
  •  go-up   go-down


21. Moslemi MK, Sadighi Gilani MA, Moslemi AA, Arabshahi A: Fournier gangrene presenting in a patient with undiagnosed rectal adenocarcinoma: a case report. Cases J; 2009;2:9136
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fournier gangrene presenting in a patient with undiagnosed rectal adenocarcinoma: a case report.
  • This case report serves to highlight an extremely unusual presentation of rectal cancer, a common surgical pathology.
  • In the course of medical and surgical treatment the presence of extensive rectal adenocarcinoma was discovered.
  • Skin grafting of necrotic areas was performed and systemic rectal cancer chemotherapy initiated after full stabilization.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2009 May;181(5):2120-6 [19286224.001]
  • [Cites] Prog Urol. 2009 Feb;19(2):75-84 [19168009.001]
  • [Cites] Med Sci Monit. 2009 Feb;15(2):CS34-39 [19179975.001]
  • [Cites] Actas Urol Esp. 2008 Nov-Dec;32(10):1024-30 [19143295.001]
  • [Cites] Mikrobiyol Bul. 2008 Oct;42(4):707-11 [19149096.001]
  • [Cites] J Pediatr Surg. 2008 Dec;43(12):e39-42 [19040919.001]
  • [Cites] Arch Esp Urol. 1999 Sep;52(7):721-7 [10540762.001]
  • [Cites] Surg Today. 2007;37(7):558-63 [17593474.001]
  • [Cites] Eur J Surg Oncol. 1997 Aug;23(4):367-8 [9315070.001]
  • [Cites] J Urol. 1992 Mar;147(3):711-2 [1538468.001]
  • [Cites] J Urol. 1978 Mar;119(3):369-71 [642092.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1213-24 [12516849.001]
  • [Cites] J Urol. 2008 Sep;180(3):944-8 [18635215.001]
  • (PMID = 20062653.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803933
  •  go-up   go-down


22. van Zyp Jv, Conway WC, Craig DH, van Zyp Nv, Thamilselvan V, Basson MD: Extracellular pressure stimulates tumor cell adhesion in vitro by paxillin activation. Cancer Biol Ther; 2006 Sep;5(9):1169-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastasizing colon cancer cells bind target tissues primarily via integrins.
  • We studied SW620 colon cancer cells and confirmed key results in Caco-2 colon cancer cells, primary human colon cancer cells, and a murine colonic adenocarcinoma.
  • Pressure stimulated adhesion and paxillin phosphorylation in SW620 and Caco-2 cells and human primary colon cancer cells.
  • In summary, pressure induced paxillin phosphorylation in colon cancer cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Paxillin / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855384.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK06771; United States / NIGMS NIH HHS / GM / T32 GM008420
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AG 1879; 0 / Collagen Type I; 0 / Paxillin; 0 / Pyrimidines; 0 / RNA, Small Interfering; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / PTK2 protein, human; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


23. Maggard MA, Yermilov I, Tomlinson JS, Ko CY: Are 12 nodes needed to accurately stage T1 and T2 colon cancers? Dig Dis Sci; 2009 Mar;54(3):640-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are 12 nodes needed to accurately stage T1 and T2 colon cancers?
  • Evaluation of 12 lymph nodes has been mandated to prevent colon cancer understaging.
  • In SEER, 61,237 patients undergoing colon cancer resection were identified.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Staging / standards

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Dis Sci. 2009 Apr;54(4):914-5; author reply 916 [19003528.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Colorectal Dis. 2008 Mar;10(3):231-8 [18257848.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Surg Oncol. 2002 Oct;81(2):63-9 [12355405.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):958-65 [10888771.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):243-5 [9922000.001]
  • [Cites] Bull Am Coll Surg. 2002 Jul;87(7):13-5 [17387902.001]
  • [Cites] J Surg Oncol. 2008 Apr 1;97(5):383-7 [18163435.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1482-6 [9554524.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):133-8 [12844262.001]
  • [Cites] Arch Surg. 2005 Sep;140(9):881-6; discussion 886-7 [16172297.001]
  • [Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):143-54; discussion 154-8 [10211489.001]
  • [Cites] Scand J Gastroenterol. 2005 Jul;40(7):858-61 [16109663.001]
  • (PMID = 18612817.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Rahman GA: Rectal cancer: pattern and outcome of management in University of Ilorin Teaching Hospital, Ilorin, Nigeria. Ann Afr Med; 2010 Jul-Sep;9(3):164-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal cancer: pattern and outcome of management in University of Ilorin Teaching Hospital, Ilorin, Nigeria.
  • BACKGROUND: Cancer of the colon and rectum was considered to be rare in Africa three to four decades ago.
  • The aim of this study is to determine the incidence of rectal cancer, its pattern of presentation, diagnosis, treatment and outcome of treatment at the University of Ilorin Teaching Hospital (UITH), Ilorin, Nigeria.
  • METHODS: This is a prospective study of all the patients with rectal cancer seen at the UITH from January 1998 to December 2002.
  • RESULTS: Thirty-six patients with rectal cancer were seen during the period.
  • CONCLUSION: Rectal cancer is not rare in Africans.
  • [MeSH-major] Adenocarcinoma / pathology. Rectal Neoplasms / pathology. Rectum / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20710108.001).
  • [ISSN] 0975-5764
  • [Journal-full-title] Annals of African medicine
  • [ISO-abbreviation] Ann Afr Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


25. Longatto-Filho A, Pinheiro C, Ferreira L, Scapulatempo C, Alves VA, Baltazar F, Schmitt F: Peritumoural, but not intratumoural, lymphatic vessel density and invasion correlate with colorectal carcinoma poor-outcome markers. Virchows Arch; 2008 Feb;452(2):133-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, peritumoural LVD, but not intratumoural, correlated with both colonic-wall-invasion depth (p = 0.037) and liver metastasis (p = 0.012).
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Lymphatic Vessels / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2006 May;448(5):570-5 [16496172.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):376-88 [12692203.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1401-9 [17640040.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1057-61 [16001629.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):45-51 [17604828.001]
  • [Cites] Cancer Lett. 2007 Feb 8;246(1-2):167-72 [16574316.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):533-9 [12851706.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):537-545 [17270246.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):729-34 [17258883.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):93-6 [17262739.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:457-83 [16212503.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6865-8 [17145802.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1317-23 [16799477.001]
  • [Cites] Dis Colon Rectum. 2007 Mar;50(3):308-14 [17164964.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1355-60 [16641900.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):821-5 [17352008.001]
  • [Cites] Am J Pathol. 2006 Aug;169(2):708-18 [16877368.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Eur Surg Res. 2006;38(5):438-44 [16912482.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1823-32 [16773076.001]
  • (PMID = 18087718.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Bembenek A, Gretschel S, Schlag PM: Sentinel lymph node biopsy for gastrointestinal cancers. J Surg Oncol; 2007 Sep 15;96(4):342-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sentinel lymph node biopsy (SLNB) in gastrointestinal-(GI)-tract cancer is not yet of clinical relevance.
  • SLNB in colon cancer still fails to show high validity to predict the nodal status, but may be helpful to clarify the prognostic role of micrometastases/isolated tumor cells.
  • In anal cancer SLNB is able to guide the indication for groin irradiation.
  • [MeSH-minor] Adenocarcinoma / pathology. Anus Neoplasms / pathology. Colonic Neoplasms / pathology. Esophageal Neoplasms / pathology. Humans. Lymphatic Metastasis. Predictive Value of Tests. Prognosis. Rectal Neoplasms / pathology. Sensitivity and Specificity. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726666.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 101
  •  go-up   go-down


27. Bień S, Kamiński B, Okła S, Kopczyński J: [Metastasis of rectal adenocarcinoma to the skull base and paranasal sinuses, with unusual clinical symptoms]. Otolaryngol Pol; 2005;59(4):627-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasis of rectal adenocarcinoma to the skull base and paranasal sinuses, with unusual clinical symptoms].
  • INTRODUCTION: The isolated distant metastasis of digestive tract adenocarcinoma, to the head and neck region is very rare.
  • MATERIAL AND METHODS: The diagnosis in 71 years female patient was based on CT, endoscopic examination and biopsy, and pathologic examination, with immunohistochemical differentiation between primary intestinal type adenocarcinoma of paranasal sinuses, and metastasis of adenocarcinoma from digestive tract.
  • The colonoscopy revealed asymptomatic primary tumor in colon.
  • CONCLUSIONS: The importance of differential diagnosis between the primary intestinal type adenocarcinoma in the upper respiratory tract and metastases of adenocarcinoma from digestive tract to head and neck region is crucial, due to entirely different type of treatment planning in both situations.
  • [MeSH-major] Adenocarcinoma / secondary. Paranasal Sinus Neoplasms / secondary. Rectal Neoplasms / pathology. Skull Base Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273875.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


28. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, González-Aguilera JJ, Fernández-Peralta AM: Effect of COX2 -765G&gt;C and c.3618A&gt;G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control; 2009 Oct;20(8):1421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer.
  • COX2 overexpression has been detected in up to 90% of colon carcinomas, and its downregulation inhibits polyp formation.
  • METHOD: We analyzed in Spanish population the risk contribution and the prognostic significance for colorectal cancer (CRC) with five polymorphisms (rs20417, rs20426, rs5276, rs13306035 and rs4648298) located in the coding and regulatory regions of COX2.
  • None of the two polymorphisms associate with colon cancer risk (HR of 1.42; 95% CI = 0.46-4.47 and 0.62; 95% CI: 0.305-1.267, respectively).
  • Moreover, the multifactor dimensionality reduction method does not detect high- or low-risk genotype combinations (training accuracy: 0.52; testing accuracy: 0.45; cross-validation consistency (CVC): 10/10; p = 0.37), indicating that there are no synergist interactions between these polymorphisms that alter the risk of cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Colorectal Neoplasms / genetics. Colorectal Neoplasms / mortality. Cyclooxygenase 2 / genetics. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19468846.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


29. Kamoshita N, Makita F, Kobayashi M, Matsuzaki Y, Kabeya K: [A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. Gan To Kagaku Ryoho; 2007 Mar;34(3):397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
  • We diagnosed adenocarcinoma of the colon in 10 patients and of the rectum in 4 patients.
  • CPT-11/5-FU/l-LV combination chemotherapy appears to be effective first-line chemotherapy for advanced and metastatic colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353631.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


30. Hörkkö TT, Tuppurainen K, George SM, Jernvall P, Karttunen TJ, Mäkinen MJ: Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int J Cancer; 2006 Apr 1;118(7):1653-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations.
  • The precursors for colorectal cancer include polypoid (conventional), flat and serrated adenomas.
  • Nuclear TRbeta1 was almost always present in normal epithelium (96%), but less frequent in adenomas (83%) and in cancer (68%; p < 0.001 and p < 0.001, respectively).
  • In Western blot analysis, a 58 kDa band corresponding to TRbeta1 was expressed in normal mucosa and in colorectal cancer specimens with positive immunohistochemistry.
  • Association of TRbeta1 expression with growth pattern and the presence of K-ras mutations suggest that abnormalities in thyroid hormone signalling involving TRbeta1 play a role in the development of some types of colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / physiopathology. Adenoma / physiopathology. Colorectal Neoplasms / physiopathology. Genes, ras. Thyroid Hormone Receptors beta / biosynthesis. Thyroid Hormone Receptors beta / physiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231318.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thyroid Hormone Receptors beta
  •  go-up   go-down


31. You JF, Hsieh LL, Changchien CR, Chen JS, Chen JR, Chiang JM, Yeh CY, Hsieh PS, Fan CW, Liu CT, Tang R: Inverse effects of mucin on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer patients. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4244-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverse effects of mucin on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer patients.
  • PURPOSE: To compare survival and histologic features of hereditary nonpolyposis colorectal cancer (HNPCC; Lynch syndrome) cases to well-matched sporadic colon cancers from the same patient population.
  • EXPERIMENTAL DESIGN: Between January 1995 and March 2002, a total of 5,138 consecutive patients underwent resection of primary colorectal adenocarcinoma in a single institution.
  • According to the Amsterdam criteria, 56 HNPCC patients were matched to 147 sporadic colorectal cancer (SCRC) with no family history of cancer and with the same gender, tumor location, and age within 3 years.
  • We noted a difference of >50% in the 5-year cancer-specific survival rates of HNPCC- and SCRC-mucinous groups (92% versus 31%, P = 0.0003).
  • Patients with tumors showing dual expression of mucin and MUC1, which appeared in 11% of those with HNPCC and 50% of those with SCRC, had a lower 5-year cancer-specific survival rate than patients without (30% versus 60%; P = 0.004 by log-rank test; P = 0.039 with adjustment for tumor-node-metastasis stage).


32. Klautke G, Feyerherd P, Ludwig K, Prall F, Foitzik T, Fietkau R: Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer; 2005 Apr 11;92(7):1215-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
  • This study aimed to evaluate the feasibility and efficacy of neoadjuvant chemoradiotherapy intensified with irinotecan in patients with locally advanced rectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):39-46 [10550825.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Strahlenther Onkol. 2000 Mar;176(3):112-7 [10742831.001]
  • [Cites] Strahlenther Onkol. 2000 Apr;176(4):161-7 [10812388.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):905-14 [11006366.001]
  • [Cites] Radiother Oncol. 2000 Oct;57(1):13-9 [11033184.001]
  • [Cites] Strahlenther Onkol. 2000 Nov;176(11):517-23 [11143526.001]
  • [Cites] Strahlenther Onkol. 2000 Dec;176(12):560-6 [11140150.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8 [12243814.001]
  • [Cites] Chest. 2002 Oct;122(4):1302-8 [12377857.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):132-7 [12504045.001]
  • [Cites] Dis Esophagus. 2003;16(1):9-16 [12581248.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1119-24 [12637479.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3098-104 [12915600.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2774-80 [15254045.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):791-9 [8478229.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3486-92 [8490898.001]
  • [Cites] Pathol Res Pract. 1994 Feb;190(2):115-23 [8058567.001]
  • [Cites] Strahlenther Onkol. 1995 Feb;171(2):70-6 [7863429.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):515-22 [9152176.001]
  • [Cites] Cancer J Sci Am. 1997 May-Jun;3(3):144-52 [9161779.001]
  • [Cites] Radiother Oncol. 1997 May;43(2):197-201 [9192967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):319-24 [9788410.001]
  • [Cites] Strahlenther Onkol. 1998 Nov;174 Suppl 3:25-9 [9830452.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3016-22 [15210740.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):605-12 [2535961.001]
  • [Cites] Int J Cancer. 1993 Jan 2;53(1):118-23 [8416195.001]
  • (PMID = 15785742.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2361958
  •  go-up   go-down


33. Pahlavan PS, Kanthan R: The epidemiology and clinical findings of colorectal cancer in Iran. J Gastrointestin Liver Dis; 2006 Mar;15(1):15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology and clinical findings of colorectal cancer in Iran.
  • BACKGROUND: This study was performed to evaluate the prevalence, clinical features and management of patients with colorectal cancer (CRC) in Iran.
  • The tumors were categorized according to their distribution as appendix (n=4), cecum ( n=7), right colon (n=1), hepatic flexure (n=2), transverse colon (n=19), splenic flexure (n=3), left colon (n=6), sigmoid ( n=16), rectum (n=117), rectosigmoid and rectal lesions (n=16), and colorectal lesions without known locations (n=9).
  • Non-mucinous adenocarcinoma (AC) was the most common histological type (n=181, 90%), followed by mucinous AC (n=15), squamous cell carcinoma (n=1), carcinoid (n=1), melanoma (n=1) and signet ring carcinoma (n=1).
  • We found no significant difference between age, gender and type of cancer with subsite distribution.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680227.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


34. Harada K, Kato J, Takemoto K, Uraoka T, Hiraoka S, Yanai H, Yamamoto K: [Case of small early cancer of sigmoid colon, which recurred with liver metastasis 18 months after surgical resection]. Nihon Shokakibyo Gakkai Zasshi; 2009 May;106(5):660-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of small early cancer of sigmoid colon, which recurred with liver metastasis 18 months after surgical resection].
  • Colonoscopic examination revealed a 7-mm 0-Is type polyp in the sigmoid colon.
  • Endoscopic mucosal resection for this lesion completely removed the lesion and the histologic diagnosis was well differentiated adenocarcinoma.
  • Cancer cells invaded the submucosa to a depth of 900 microm, and vascular invasion was found.
  • [MeSH-major] Adenocarcinoma / secondary. Liver Neoplasms / secondary. Neoplasm Recurrence, Local. Neoplasms, Second Primary. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420870.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


35. Agha A, Fürst A, Iesalnieks I, Fichtner-Feigl S, Ghali N, Krenz D, Anthuber M, Jauch KW, Piso P, Schlitt HJ: Conversion rate in 300 laparoscopic rectal resections and its influence on morbidity and oncological outcome. Int J Colorectal Dis; 2008 Apr;23(4):409-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colectomy / methods. Laparoscopy / statistics & numerical data. Laparotomy / statistics & numerical data. Postoperative Complications / epidemiology. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Arch Surg. 1997 Jan;132(1):41-4; discussion 45 [9006551.001]
  • [Cites] Surg Endosc. 2001 Aug;15(8):827-32 [11443444.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):83-91 [15973105.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Chirurg. 2006 Aug;77(8):709-17 [16799790.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):963-70 [9715150.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1406-8 [7489179.001]
  • [Cites] Surg Endosc. 2004 May;18(5):732-5 [15216851.001]
  • [Cites] Surg Endosc. 2002 May;16(5):855-8 [11997837.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):217-22 [11227938.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):207-14; discussion 214-6 [11227937.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1680-5 [15540299.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):592-6 [9152190.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Surg Endosc. 1999 Feb;13(2):151-6 [9918619.001]
  • [Cites] Surg Endosc. 2001 Dec;15(12):1431-9 [11965460.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):451-3 [12925079.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):116-20 [11285950.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):413-24 [16450220.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • (PMID = 18185938.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Saif MW, Siddiqui IA, Sohail MA: Management of ascites due to gastrointestinal malignancy. Ann Saudi Med; 2009 Sep-Oct;29(5):369-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancers associated with ascites are adenocarcinomas of the ovary, breast, colon, stomach and pancreas.
  • There are many potential causes of ascites in cancer patients, including peritoneal carcinomatosis, malignant obstruction of draining lymphatics, portal vein thrombosis, elevated portal venous pressure from cirrhosis, congestive heart failure, constrictive pericarditis, nephrotic syndrome and peritoneal infections.
  • Median survival after diagnosis of malignant ascites is in the range of 1 to 4 months; survival is apt to be longer for ovarian and breast cancers if systemic anti-cancer treatments are available.
  • [MeSH-major] Adenocarcinoma / complications. Ascites / therapy. Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Oct;31(7):626-34 [10604107.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1207-14 [9816289.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):445-54 [10675474.001]
  • [Cites] Palliat Med. 2000 Jan;14(1):62-4 [10717726.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2733-7 [11732940.001]
  • [Cites] Palliat Med. 2002 May;16(3):213-8 [12046997.001]
  • [Cites] Hepatology. 2003 Jul;38(1):258-66 [12830009.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1646-54 [15084697.001]
  • [Cites] Surgery. 1974 Feb;75(2):299-304 [4590763.001]
  • [Cites] Arch Intern Med. 1979 Feb;139(2):235 [434979.001]
  • [Cites] Am J Clin Oncol. 1982 Apr;5(2):167-72 [6178284.001]
  • [Cites] Br J Surg. 1982 Aug;69(8):441-2 [7049306.001]
  • [Cites] J Surg Oncol. 1982 Aug;20(4):238-42 [6180252.001]
  • [Cites] Br J Surg. 1983 Aug;70(8):478-81 [6871638.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Mar 10;288(6419):749-51 [6423061.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2226-30 [6207907.001]
  • [Cites] Cancer. 1985 May 1;55(9):1973-8 [3978577.001]
  • [Cites] Hepatology. 1985 May-Jun;5(3):403-7 [3888808.001]
  • [Cites] Cancer Treat Rev. 1985 Dec;12 Suppl B:23-32 [3833327.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):644-51 [3718029.001]
  • [Cites] Hepatology. 1988 Sep-Oct;8(5):1104-9 [3417231.001]
  • [Cites] Adv Intern Med. 1990;35:365-73 [2405598.001]
  • [Cites] Ann Intern Med. 1990 Jun 15;112(12):889-91 [2187389.001]
  • [Cites] Eur J Cancer. 1991;27(2):121-5 [1827272.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Mar-Apr;7(2):161-4 [1571498.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1302-6 [1397889.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):102-9 [1427388.001]
  • [Cites] Cancer. 1993 Mar 15;71(6):2027-30 [7680276.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):337-42 [8277955.001]
  • [Cites] Am J Hosp Pharm. 1994 May 1;51(9):1184-92 [8042637.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):378-81 [7531600.001]
  • [Cites] Hepatology. 1996 Jan;23(1):164-76 [8550036.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2201-6 [8572625.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):6-14 [8653366.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):237-9 [8654603.001]
  • [Cites] Medsurg Nurs. 1995 Dec;4(6):468-71 [8696395.001]
  • [Cites] N Z Med J. 1997 Feb 14;110(1037):33-5 [9066565.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1899-902 [9717817.001]
  • [Cites] J Pain Symptom Manage. 1998 Aug;16(2):96-101 [9737100.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):381-5 [9887235.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):300-8 [16240400.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):589-97 [16434188.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):709-13 [16739342.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):908-13 [17140897.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2348-57 [17505860.001]
  • [Cites] J Nippon Med Sch. 2007 Oct;74(5):355-8 [17965529.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Dec;22(12):2161-6 [18031375.001]
  • [Cites] QJM. 2008 Feb;101(2):71-85 [18184668.001]
  • [Cites] Palliat Med. 1999 Sep;13(5):429-30 [10659116.001]
  • (PMID = 19700895.001).
  • [ISSN] 0975-4466
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC3290049
  •  go-up   go-down


37. Shida K, Misonou Y, Korekane H, Seki Y, Noura S, Ohue M, Honke K, Miyamoto Y: Unusual accumulation of sulfated glycosphingolipids in colon cancer cells. Glycobiology; 2009 Sep;19(9):1018-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual accumulation of sulfated glycosphingolipids in colon cancer cells.
  • The structures of glycosphingolipids from highly purified colorectal cancer cells and normal colorectal epithelial cells of 16 patients have been analyzed in fine detail (Misonou Y, Shida K, Korekane H, Seki Y, Noura S, Ohue M, Miyamoto Y. 2009.
  • Comprehensive Clinico-Glycomic Study of 16 Colorectal Cancer Specimens: Elucidation of aberrant glycosylation and ts mechanistic causes in colorectal cancer cells.
  • Further structural analyses demonstrated that colon cancer cells from two patients accumulated unusual glycosphingolipids which were not observed in either colorectal cancer cells or normal colorectal epithelial cells from the other patients.
  • The structures of the glycosphingolipids of the cancer cells from these two cases were analyzed by methods which include enzymatic release of carbohydrate moieties, fluorescent labeling with aminopyridine and identification using two-dimensional mapping, enzymatic digestion and mass spectrometry together with methanolysis, and the use of newly synthesized sulfo-fucosylated oligosaccharides as standards.
  • The colon cancer cells from one of the patients demonstrate a variety of oligosaccharides as major components which are sulfated at the C6 position of subterminal GlcNAc and at C3 positions of terminal galactose with or without sialylation or fucosylation.
  • The colon cancer cells from the other patient have two kinds of sulfated oligosaccharides, a 6-sulfo Le(x) structure and a 3'-sulfo Le(x) structure, as minor components.
  • Taking into consideration the clinical features of the two patients, the biological significance of sulfated glycosphingolipids on cancer cells is discussed.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Glycosphingolipids / metabolism. Sulfates / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19541771.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycosphingolipids; 0 / Sulfates
  •  go-up   go-down


38. Chan AC, Poon JT, Fan JK, Lo SH, Law WL: Impact of conversion on the long-term outcome in laparoscopic resection of colorectal cancer. Surg Endosc; 2008 Dec;22(12):2625-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of conversion on the long-term outcome in laparoscopic resection of colorectal cancer.
  • BACKGROUND: Long-term outcome of patients with conversion following laparoscopic resection of colorectal cancer has seldom been reported.
  • Consequently, patients in the conversion group were more likely to develop local recurrence (9.8% versus 2.8%, P < 0.001) with a significantly reduced cumulative cancer-free survival.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy / statistics & numerical data. Laparotomy / statistics & numerical data

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):39-42 [14718273.001]
  • [Cites] Arch Surg. 1997 Jan;132(1):41-4; discussion 45 [9006551.001]
  • [Cites] Surg Endosc. 2001 Aug;15(8):827-32 [11443444.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):83-91 [15973105.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):503-9 [12682545.001]
  • [Cites] Surg Endosc. 2004 May;18(5):732-5 [15216851.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):207-14; discussion 214-6 [11227937.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1680-5 [15540299.001]
  • [Cites] Surg Endosc. 2000 Dec;14(12):1114-7 [11148778.001]
  • [Cites] J Am Coll Surg. 2004 Nov;199(5):675-9 [15501105.001]
  • [Cites] Dis Colon Rectum. 2006 Feb;49(2):197-204 [16328607.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):47-54 [15549630.001]
  • [Cites] Surg Endosc. 1997 Apr;11(4):331-5 [9094271.001]
  • [Cites] Surg Endosc. 2006 Jun;20(6):947-51 [16738988.001]
  • (PMID = 18297346.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Giovannini I, Giuliante F, Chiarla C, Ardito F, Vellone M, Nuzzo G: Non-surgical management of a lymphatic fistula, after laparoscopic colorectal surgery, with total parenteral nutrition, octreotide, and somatostatin. Nutrition; 2005 Oct;21(10):1065-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We report the case of an external lymphatic fistula that appeared through an abdominal drainage after laparoscopic resection of the rectum and sigmoid colon for cancer, with lymphadenectomy.
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Drainage. Humans. Ileostomy / adverse effects. Lymph Node Excision / adverse effects. Male. Rectal Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Fistulas.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157245.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


40. Rooney S, Ryan MF: Effects of alpha-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines. Anticancer Res; 2005 May-Jun;25(3B):2199-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of alpha-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines.
  • The separate effects of alpha-hederin and thymoquinone, the two principal bioactive constituents of Nigella sativa, on four human cancer cell lines [A549 (lung carcinoma), HEp-2 (larynx epidermoid carcinoma), HT-29 (colon adenocarcinoma) and MIA PaCa-2 (pancreas carcinoma)] were investigated.
  • So, the membrane-perforating properties associated with saponins, here represented by alpha-hederin, enhance neither cytotoxicity nor apoptosis of these cancer cells.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Apoptosis / drug effects. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. HT29 Cells. Humans. Inhibitory Concentration 50. Laryngeal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Necrosis. Nigella sativa / chemistry. Pancreatic Neoplasms / drug therapy. Prodrugs / pharmacology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158964.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Drugs, Chinese Herbal; 0 / Prodrugs; 0 / Saponins; 27013-91-8 / alpha-hederin; 490-91-5 / thymoquinone; 6SMK8R7TGJ / Oleanolic Acid
  •  go-up   go-down


41. Yi JY, Jung YJ, Choi SS, Hwang J, Chung E: Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2 cells. Biochem Biophys Res Commun; 2009 Aug 28;386(3):455-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its anti-tumoral effects have been previously demonstrated in a variety of cancer cells, and were identified as indirect responses mediated by the immune modulation of cutaneous dendritic cells.
  • In this study, we first observed IMQ-initiated autophagy determined by vesicular organelle formation and the generation of LC3-II in Caco-2 human colonic adenocarcinoma cells, which expressing functional TLR7.
  • In conclusion, the modulation of autophagy might be applied in a potential cancer therapy for the treatment of colon cancer cells.

  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527683.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ligands; 0 / TLR7 protein, human; 0 / Toll-Like Receptor 7; 99011-02-6 / imiquimod
  •  go-up   go-down


42. Kooby DA: Laparoscopic pancreatic resection for cancer. Expert Rev Anticancer Ther; 2008 Oct;8(10):1597-609
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pancreatic resection for cancer.
  • Laparoscopic (lap) organ resection is now commonly performed for the management of solid tumors of the kidney, colon, adrenal glands and prostate.
  • As neoplastic disease is the most common indication for pancreatic resection, understanding the effects of the lap approach to pancreatectomy on cancer outcome is crucial.
  • This review covers the development and current state-of-the-art of lap pancreatic surgery for cancer.
  • Existing data are reviewed for both open and lap pancreatic resections, with particular attention to pancreatic ductal adenocarcinoma.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18925852.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 98
  •  go-up   go-down


43. Horwhat JD, Gerke H, Acosta RD, Pavey DA, Jowell PS: Focal or diffuse "fullness" of the pancreas on CT. Usually benign, but EUS plus/minus FNA is warranted to identify malignancy. JOP; 2009;10(1):37-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: FNA was performed in 19/69 (27.5%) with 4 new diagnoses of pancreatic adenocarcinoma, one metastatic renal cell carcinoma, one metastatic colon cancer, one chronic pancreatitis and 12 benign results.


44. de Ferro SM, Suspiro A, Fidalgo P, Lage P, Rodrigues P, Fragoso S, Vitoriano I, Baltazar C, Albuquerque C, Bettencourt A, Leitão CN: Aggressive phenotype of MYH-associated polyposis with jejunal cancer and intra-abdominal desmoid tumor: report of a case. Dis Colon Rectum; 2009 Apr;52(4):742-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive phenotype of MYH-associated polyposis with jejunal cancer and intra-abdominal desmoid tumor: report of a case.
  • MYH-associated polyposis is an inherited autosomal recessive disease, linked to biallelic germline MYH mutations, which predisposes to the development of multiple colorectal adenomas and cancer.
  • The colonic and extracolonic phenotype of this syndrome is very heterogeneous.
  • He presented at aged 30 years with more than 100 colonic polyps and 4 colonic adenocarcinomas.
  • When he was 39 years old, he developed three synchronous jejunal adenocarcinomas and a mesenteric desmoid tumor.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenoma / genetics. Adult. DNA Glycosylases / genetics. Duodenal Neoplasms / genetics. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Intestinal Neoplasms / genetics. Intestinal Obstruction / etiology. Liver Neoplasms / secondary. Male. Mesentery. Mutation. Phenotype. Syndrome


45. Bhatnagar N, Li X, Chen Y, Zhou X, Garrett SH, Guo B: 3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev Res (Phila); 2009 Jun;2(6):581-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin.
  • Butyrate is an inhibitor of histone deacetylase (HDAC) and has been extensively evaluated as a chemoprevention agent for colon cancer.
  • We recently showed that mutations in the adenomatous polyposis coli (APC) gene confer resistance to HDAC inhibitor-induced apoptosis in colon cancers.
  • Here, we show that APC mutation rendered colon cancer cells resistant to butyrate-induced apoptosis due to the failure of butyrate to down-regulate survivin in these cells.
  • Another cancer-preventive agent, 3,3'-diindolylmethane (DIM), was identified to be able to down-regulate survivin in colon cancers expressing mutant APC.
  • Pretreatment with DIM enhanced butyrate-induced apoptosis in colon cancer cells expressing mutant APC.
  • Whereas overexpression of survivin blocked DIM/butyrate-induced apoptosis, knocking down of survivin by small interfering RNA increased butyrate-induced apoptosis in colon cancer cells.
  • Thus, the combination of DIM and butyrate is potentially an effective strategy for the prevention of colon cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3288-93 [8205551.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):230-5 [12517802.001]
  • [Cites] Epithelial Cell Biol. 1994 Jul;3(3):119-25 [7894569.001]
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):638-42 [8757136.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7950-4 [8755583.001]
  • [Cites] Cell Growth Differ. 1997 May;8(5):523-32 [9149903.001]
  • [Cites] J Nutr. 1997 Nov;127(11):2217-25 [9349850.001]
  • [Cites] Chem Biol. 1997 Nov;4(11):783-9 [9384528.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):11177-82 [9556606.001]
  • [Cites] Nutr Cancer. 1998;30(3):175-81 [9631487.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):3878-85 [9670005.001]
  • [Cites] Oncol Res. 1999;11(2):91-9 [10489165.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1911-22 [16084718.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):13-8 [12892709.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):535-41 [14735205.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] J Nutr. 2004 Feb;134(2):479-82 [14747692.001]
  • [Cites] Cancer Cell. 2004 May;5(5):455-63 [15144953.001]
  • [Cites] Carcinogenesis. 2004 Jul;25(7):1129-36 [14764461.001]
  • [Cites] Gastroenterology. 1982 Aug;83(2):424-9 [7084619.001]
  • [Cites] Gastroenterology. 1986 Sep;91(3):596-602 [3732764.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2874-8 [1851662.001]
  • [Cites] Science. 1992 Apr 3;256(5053):102-5 [1566048.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3801-3 [1319833.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1201-15 [16082211.001]
  • [Cites] Carcinogenesis. 2006 Feb;27(2):344-9 [16267097.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40(3):235-43 [16633129.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4880-7 [16651444.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4952-60 [16651453.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9245-51 [16982769.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10064-72 [17047070.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1833-42 [17071604.001]
  • [Cites] J Nutr. 2007 Jan;137(1):31-6 [17182797.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2757-65 [17913854.001]
  • [Cites] J Nutr. 2007 Nov;137(11 Suppl):2576S-2579S [17951506.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1927-34 [18339874.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):498-505 [8397167.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Cell. 2000 Jul 7;102(1):33-42 [10929711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13103-7 [11069302.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1389-99 [11163212.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):525-7 [11238196.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Physiol Rev. 2001 Jul;81(3):1031-64 [11427691.001]
  • [Cites] Curr Biol. 2001 Jun 5;11(11):886-90 [11516652.001]
  • [Cites] Curr Med Chem. 2001 Oct;8(12):1505-11 [11562279.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):981-90 [11581299.001]
  • [Cites] J Natl Cancer Inst. 2001 Oct 17;93(20):1541-52 [11604477.001]
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2922-33 [11711427.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):194-202 [11902574.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):165-6 [12242145.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5953-8 [7954428.001]
  • (PMID = 19470789.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA130062; United States / NCI NIH HHS / CA / 5R21CA111765; United States / NCRR NIH HHS / RR / 2P20RR015566; United States / NCI NIH HHS / CA / 1R03CA130062; United States / NCI NIH HHS / CA / R03 CA130062-02; United States / NIGMS NIH HHS / GM / P30 GM103332; United States / NCRR NIH HHS / RR / P20 RR015566; United States / NCRR NIH HHS / RR / P20 RR015566-08; United States / NCRR NIH HHS / RR / RR015566-08; United States / NCI NIH HHS / CA / R21 CA111765; United States / NCI NIH HHS / CA / CA130062-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / BIRC5 protein, human; 0 / Butyrates; 0 / DNA, Complementary; 0 / Histone Deacetylase Inhibitors; 0 / Indoles; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Recombinant Fusion Proteins; SSZ9HQT61Z / 3,3'-diindolylmethane
  • [Other-IDs] NLM/ NIHMS209111; NLM/ PMC2901098
  •  go-up   go-down


46. Falciani C, Lelli B, Brunetti J, Pileri S, Cappelli A, Pini A, Pagliuca C, Ravenni N, Bencini L, Menichetti S, Moretti R, De Prizio M, Scatizzi M, Bracci L: Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proof-of-concept. Curr Cancer Drug Targets; 2010 Nov;10(7):695-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tetra-branched peptides containing neurotensin (NT) sequence are described here as selective targeting agents for human colon, pancreas and prostate cancer.
  • Cytotoxicity on human cell lines from colon (HT-29), pancreas (PANC-1) or prostate (PC-3) carcinoma indicated branched NT conjugated with MTX and 5-FdU as the most active agents on PANC-1 (EC(50) 4.4e-007 M) and HT-29 (1.1e-007 M), respectively.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Colonic Neoplasms / drug therapy. Drug Carriers / pharmacology. Neurotensin / analogs & derivatives. Oligopeptides / pharmacology. Pancreatic Neoplasms / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Animals. Biological Transport. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Female. Humans. Inhibitory Concentration 50. Male. Mice. Mice, Nude. Middle Aged. Receptors, Peptide / metabolism. Tumor Burden / drug effects. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578987.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Drug Carriers; 0 / Oligopeptides; 0 / Receptors, Peptide; 39379-15-2 / Neurotensin
  •  go-up   go-down


47. Heinzerling JH, Huerta S: Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg; 2006 Sep-Oct;63(5):334-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
  • Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer.
  • [MeSH-major] Abdomen, Acute / chemically induced. Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Intestinal Perforation / chemically induced. Neoplasm Recurrence, Local / drug therapy. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971205.001).
  • [ISSN] 0149-7944
  • [Journal-full-title] Current surgery
  • [ISO-abbreviation] Curr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


48. Klimek-Tomczak K, Mikula M, Dzwonek A, Paziewska A, Karczmarski J, Hennig E, Bujnicki JM, Bragoszewski P, Denisenko O, Bomsztyk K, Ostrowski J: Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa. Br J Cancer; 2006 Feb 27;94(4):586-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa.
  • To explore the possibility that there are alternative isoforms of K protein expressed in colon cancer, we amplified and sequenced K protein mRNA that was isolated from colorectal cancers as well as from normal tissues surrounding the tumours.
  • Sequencing of RNA from normal colonic mucosa of patients with prior resection of colorectal cancer revealed only the wild-type K protein transcript, indicating that G274A isoform is tumour related.
  • To our knowledge, this is the first example of an RNA editing event in cancer and its surrounding tissue, a finding that may offer a new diagnostic and treatment marker.
  • [MeSH-major] Colonic Neoplasms / genetics. Heterogeneous-Nuclear Ribonucleoprotein K / genetics. RNA Editing

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9699-704 [11121407.001]
  • [Cites] Annu Rev Genet. 2000;34:499-531 [11092837.001]
  • [Cites] J Clin Invest. 2002 Feb;109(3):291-4 [11827986.001]
  • [Cites] RNA. 2002 Mar;8(3):265-78 [12003487.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3476-85 [12093748.001]
  • [Cites] Biochimie. 2002 Aug;84(8):791-803 [12457566.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):695-8 [12431975.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):1391-4 [12446659.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 15;31(14):3954-62 [12853611.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1493-501 [14562022.001]
  • [Cites] Mutagenesis. 2004 Jan;19(1):3-11 [14681308.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):399-409 [14726492.001]
  • [Cites] Bioessays. 2004 Jun;26(6):629-38 [15170860.001]
  • [Cites] Nat Struct Mol Biol. 2004 Oct;11(10):950-6 [15361858.001]
  • [Cites] J Mol Biol. 1994 Feb 11;236(1):33-48 [8107114.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 25;22(6):959-64 [8152927.001]
  • [Cites] Receptors Channels. 1994;2(4):315-26 [7719709.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9494-9 [7721877.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2350-60 [8628302.001]
  • [Cites] Biochem Soc Trans. 1996 Feb;24(1):274-9 [8674685.001]
  • [Cites] FEBS Lett. 1997 Feb 17;403(2):113-5 [9042948.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1096-103 [9797364.001]
  • [Cites] Trends Genet. 2004 Dec;20(12):604-10 [15522455.001]
  • [Cites] FEBS Lett. 2004 Nov 5;577(1-2):134-40 [15527774.001]
  • [Cites] Genome Res. 2004 Dec;14(12):2379-87 [15545495.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54599-609 [15485813.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Trends Genet. 2005 Feb;21(2):77-81 [15661352.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3946-53 [15556947.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1061-5 [15718460.001]
  • [Cites] J Cell Biol. 2005 Jun 6;169(5):745-53 [15939761.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] Bioessays. 2000 Sep;22(9):790-802 [10944581.001]
  • [Cites] Science. 2000 Sep 1;289(5484):1564-6 [10968794.001]
  • [Cites] Trends Biochem Sci. 2001 Jun;26(6):376-84 [11406411.001]
  • (PMID = 16404425.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Heterogeneous-Nuclear Ribonucleoprotein K; 0 / Protein Isoforms
  • [Other-IDs] NLM/ PMC2361188
  •  go-up   go-down


49. Wang X, Chen W, Li X, Lin H, Wang Q: Heat shock protein 72 associated with CD44v6 in human colonic adenocarcinoma. Cell Biol Int; 2008 Jul;32(7):860-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat shock protein 72 associated with CD44v6 in human colonic adenocarcinoma.
  • CD44v6 is a splice variant of CD44 (CD44v), probably promoting cancer cell adherence to vascular endothelium and base membranes and enhancing the invasion and metastasis of colonic carcinomas.
  • There may be a possible association between the expression of HSP72 and CD44v6 during the growth and progression of colonic carcinoma cells.
  • The aim of the study was to investigate the interaction between heat shock protein 72 and CD44v6 in human colonic carcinomas.
  • The localization of HSP72 and CD44v6 in human colonic carcinomas was determined by immunohistochemistry and confocal laser microscopy.
  • The interaction between HSP72 and CD44v6 in colonic carcinoma cells was analyzed by immunoprecipitation and Western immunoblots.
  • Our results revealed that colonic carcinoma synchronously co-expressed higher levels of HSP72 and CD44v6 than that in adjacent normal colonic tissues.
  • Based on immunoprecipitation and Western immunoblots, we found that HSP72 was associated with CD44v6 precursor fragments in human colonic carcinoma cells.
  • The interaction between HSP72 and CD44v6 in human colonic carcinoma cells may contribute to study the pathogenesis and immunotherapy of colonic carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD44 / metabolism. Colonic Neoplasms / metabolism. HSP72 Heat-Shock Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387829.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / HSP72 Heat-Shock Proteins; 0 / Protein Isoforms
  •  go-up   go-down


51. Bini EJ, Park J, Francois F: Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med; 2006 Aug 14-28;166(15):1626-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older.
  • BACKGROUND: Although many patients with human immunodeficiency virus (HIV) infection are now living well beyond 50 years of age, there are no data available on colorectal cancer screening in this population.
  • METHODS: Consecutive patients at average risk for colorectal cancer who were referred for screening flexible sigmoidoscopy were prospectively identified.
  • The prevalence of neoplastic lesions (adenomas or adenocarcinomas) in the distal colon was significantly higher in HIV-infected patients than in control subjects (25.5% vs 13.1%, P<.001), and the odds of HIV-infected patients having a neoplastic lesion was significantly higher even after adjustment for potential confounding variables (odds ratio, 2.34; 95% confidence interval, 1.60-3.44).
  • The prevalence of adenomas of any size (25.5% vs 12.9%, P<.001) and advanced neoplasia (7.3% vs 3.8%, P = .03) in the distal colon was significantly higher in HIV-infected patients.
  • Among individuals with positive results on flexible sigmoidoscopy, proximal colonic neoplastic lesions on follow-up colonoscopy were more common in HIV-infected patients after adjustment for age, sex, and race/ethnicity (odds ratio, 1.88; 95% confidence interval, 1.02-3.46).
  • CONCLUSIONS: Patients infected with HIV are more likely to have colonic neoplasms on screening flexible sigmoidoscopy than those without HIV, and these individuals should be offered colorectal cancer screening.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma / epidemiology. Aged. Female. Health Status. Humans. Male. Middle Aged


52. Greenblatt DY, Weber SM, O'Connor ES, LoConte NK, Liou JI, Smith MA: Readmission after colectomy for cancer predicts one-year mortality. Ann Surg; 2010 Apr;251(4):659-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Readmission after colectomy for cancer predicts one-year mortality.
  • We sought to determine the rate and predictors of readmission after colectomy for cancer, as well as the association between readmission and mortality.
  • METHODS: Medicare beneficiaries who underwent colectomy for stage I to III colon adenocarcinoma from 1992 to 2002 were identified from the Surveillance, Epidemiology, and End Results-Medicare database.
  • This difference in mortality was significant for all stages of cancer.
  • CONCLUSIONS: Early readmission after colectomy for cancer is common and due in part to modifiable factors.
  • Early readmission is therefore an important quality-of-care indicator for colon cancer surgery.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Apr 24;160(8):1074-81 [10789599.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1418-28 [19339721.001]
  • [Cites] Health Care Financ Rev. 2000 Spring;21(3):7-28 [11481769.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):942-6 [11496073.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1533-8 [11683754.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1855-9; discussion 1859-60 [11789760.001]
  • [Cites] J Am Geriatr Soc. 2001 Nov;49(11):1561-4 [11890600.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-62-8 [12187170.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):503-9 [12682545.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):432-7 [12749241.001]
  • [Cites] J Surg Oncol. 2003 Jun;83(2):68-78; discussion 78-9 [12772198.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):851-9 [12847356.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):161-7 [12894006.001]
  • [Cites] JAMA. 2003 Aug 13;290(6):773-80 [12915430.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1112-7 [14597452.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1497-504 [14648727.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):877-83 [15194068.001]
  • [Cites] J Am Coll Surg. 2004 Nov;199(5):675-9 [15501105.001]
  • [Cites] Br J Prev Soc Med. 1965 Oct;19(4):182-91 [5845379.001]
  • [Cites] Am J Med. 1991 Jun;90(6):667-74 [2042681.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Conn Med. 1995 May;59(5):263-70 [7600797.001]
  • [Cites] Health Serv Res. 1995 Aug;30(3):489-506 [7649753.001]
  • [Cites] J Qual Clin Pract. 1995 Dec;15(4):211-20 [8719060.001]
  • [Cites] Med Care. 1997 Oct;35(10):1044-59 [9338530.001]
  • [Cites] J Am Coll Surg. 1998 May;186(5):501-6 [9583689.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):416-23 [15729063.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1463-8 [15791370.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1381-7 [10566524.001]
  • [Cites] J Epidemiol Community Health. 2005 Jun;59(6):506-11 [15911648.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):629-39 [15983985.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1354-62 [16237744.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1243-52; discussion 1252-3 [17114011.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):73-9 [17197968.001]
  • [Cites] Arch Intern Med. 2007 Feb 12;167(3):258-64 [17296881.001]
  • [Cites] Am J Manag Care. 2007 Mar;13(3):157-64 [17335359.001]
  • [Cites] J Am Geriatr Soc. 2007 Mar;55(3):365-73 [17341238.001]
  • [Cites] Curr Probl Cancer. 2007 May-Jun;31(3):123-33 [17543944.001]
  • [Cites] Br J Surg. 2007 Jul;94(7):890-3 [17330930.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1316-23 [17665252.001]
  • [Cites] Cancer Biomark. 2007;3(6):301-13 [18048968.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2430-5 [18246608.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):900-8 [18181101.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):51-7 [10862195.001]
  • (PMID = 20224370.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N02-PC-15105; United States / PHS HHS / / U55/CCR921930 - 02; None / None / / UL1 RR025011-01; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCRR NIH HHS / RR / UL1 RR025011-01; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCRR NIH HHS / RR / 1UL1RR025011; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-35136
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230999; NLM/ PMC2951007
  •  go-up   go-down


53. Chaturvedi A, Jambhekar N: Well-differentiated adenocarcinoma of the rectosigmoid colon associated with psammoma bodies: a case report. Indian J Pathol Microbiol; 2007 Apr;50(2):399-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated adenocarcinoma of the rectosigmoid colon associated with psammoma bodies: a case report.
  • This report documents an unusualfinding of scattered psammomatous-type calcification in a well-differentiated adenocarcinoma of the rectosigmoid colon in a 54-year-old woman.
  • [MeSH-major] Adenocarcinoma / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883090.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


54. Traba Villameytide ML, Orts Costa JA, Morell M: [Study of a intestinal enteroliths in human patient with colon adenocarcinoma. Is it similar to renal calculi?]. Actas Urol Esp; 2006 Feb;30(2):206-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of a intestinal enteroliths in human patient with colon adenocarcinoma. Is it similar to renal calculi?].
  • [Transliterated title] Estudio de un cálculo intestinal en un paciente con adenocarcinoma de colón. Es similar a los cálculos renales?
  • This enterolithis is associated with colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Calculi / chemistry. Calculi / complications. Colonic Neoplasms / complications. Intestinal Diseases / complications. Kidney Calculi / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700212.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


55. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G: Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer; 2007 Apr 10;96(7):1118-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
  • In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.
  • Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]
  • [Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]
  • [Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]
  • (PMID = 17375048.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2360113
  •  go-up   go-down


56. Hyland R, Jones B, van de Waterbeemd H: Utility of human/human-derived reagents in drug discovery and development: An industrial perspective. Environ Toxicol Pharmacol; 2006 Feb;21(2):179-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In terms of drug absorption, the human colon adenocarcinoma cell line, Caco-2, offers a versatile human derived system for measuring drug permeability, despite over expression of the efflux transporter P-glycoprotein (P-gp).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21783655.001).
  • [ISSN] 1382-6689
  • [Journal-full-title] Environmental toxicology and pharmacology
  • [ISO-abbreviation] Environ. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Samaritan G, Pearlman RA: Underdiagnosed and undertreated colorectal cancer tops liability list. J Med Assoc Ga; 2007;96(1):48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underdiagnosed and undertreated colorectal cancer tops liability list.
  • After routine colon prep, the surgeon performed a flexible sigmoidoscopy.
  • The pathology report noted an adenocarcinoma of the colon.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621908.001).
  • [ISSN] 0025-7028
  • [Journal-full-title] Journal of the Medical Association of Georgia
  • [ISO-abbreviation] J Med Assoc Ga
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Huang G, Zhong X, Cao Y, Chen Y: Antiproliferative effects of conjugated linoleic acid on human colon adenocarcinoma cell line Caco-2. Asia Pac J Clin Nutr; 2007;16 Suppl 1:432-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative effects of conjugated linoleic acid on human colon adenocarcinoma cell line Caco-2.
  • The antiproliferative effects of two isomers of CLA (c9, t11-CLA, t9, t11-CLA) and their mixture on the human colon adenocarcinoma cell line Caco-2 were investigated in this paper.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Division / drug effects. Colonic Neoplasms / drug therapy. Linoleic Acids, Conjugated / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392145.001).
  • [ISSN] 0964-7058
  • [Journal-full-title] Asia Pacific journal of clinical nutrition
  • [ISO-abbreviation] Asia Pac J Clin Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Linoleic Acids, Conjugated; 1839-11-8 / 9,11-linoleic acid
  •  go-up   go-down


59. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, Perucho M: Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell; 2006 Mar;9(3):199-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage.
  • We studied the relationships between genetic and epigenetic alterations in gastrointestinal cancer by integrating DNA copy number changes determined by arbitrarily primed PCR (AP-PCR) with DNA methylation variations estimated by methylation-sensitive amplified fragment length polymorphism (MS-AFLP).
  • We analyzed about 100 different chromosomal regions by AP-PCR and over 150 random CpG loci by MS-AFLP in human colon and gastric carcinomas.
  • DNA hypomethylation and hypermethylation alterations distributed gradually and increased with cancer patient age, in contrast with the age-independent genomic alterations.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. DNA, Neoplasm / chemistry. Gastrointestinal Neoplasms / genetics


60. Brahmania M, Kanthan CS, Kanthan R: Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor. World J Surg Oncol; 2007;5:118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor.
  • BACKGROUND: Collision tumors of the colon are rare.
  • We report the first case, to our knowledge in the English literature, of a collision tumor composed of a colonic adenocarcinoma arising in a sigmoid diverticulum coexisting with a recurrent ovarian granulosa cell tumor.
  • Surgical removal of the mass and pathological examination revealed the presence of a colonic adenocarcinoma arising in a large sigmoid diverticulum coexistent with a second neoplastic tumor phenotype; confirmed to be a delayed recurrent ovarian granulosa cell tumor.
  • CONCLUSION: Collision tumors of the colon are rare.
  • This is the first case reported of a collision tumor composed of adenocarcinoma colon and recurrent granulosa cell tumor representing an example of two independent tumors in a unique one-on-another collision.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Granulosa Cell Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ceska Gynekol. 2000 May;65(3):163-6 [10953492.001]
  • [Cites] Rom J Morphol Embryol. 2007;48(1):75-8 [17502956.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):188-92 [14530814.001]
  • [Cites] Cancer. 1976 Jul;38(1):335-40 [181131.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):822-4 [6389052.001]
  • [Cites] Gastroenterol Clin Biol. 1990;14(2):185-6 [2328885.001]
  • [Cites] Surgery. 1993 Feb;113(2):223-6 [8430371.001]
  • [Cites] J Surg Oncol. 1994 Feb;55(2):71-7 [8121188.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):484-8 [8774662.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):538-9 [8870012.001]
  • [Cites] Indian J Gastroenterol. 1997 Jan;16(1):28-9 [9167378.001]
  • [Cites] Arch Pathol Lab Med. 1998 Mar;122(3):262-5 [9823866.001]
  • [Cites] Surg Oncol. 2005 Jul;14(1):11-25 [15777886.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2758-9 [12498297.001]
  • (PMID = 17949502.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164962
  •  go-up   go-down


61. Snaebjörnsson P, Jónasson L, Jónsson T, Möller PH, Theodórs A, Jónasson JG: [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference]. Laeknabladid; 2009 Jun;95(6):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].
  • OBJECTIVE: Colon cancer is the third most common cancer in Iceland.
  • The aim of this study was to analyze the epidemiology and histopathology of colon cancer in Iceland, resection rate and the difference between men and women.
  • MATERIAL AND METHODS: Pathology and autopsy reports for all patients diagnosed with colon cancer between 1955 and 2004 where reviewed.
  • Most tumors were located in the sigmoid colon (35%).
  • Adenocarcinomas where 84% and mucinous adenocarcinoma 7%.
  • CONCLUSION: Incidence of colon cancer increased considerably, mainly for men.
  • Surgical rate and pathology of colon cancer is similar to that reported elsewhere except that there are somewhat fewer cases in TNM-stage I.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laeknabladid. 2009 Jun;95(6):419 [19491405.001]
  • (PMID = 19491407.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


62. Meroni E, Gatteschi B, Fasoli A, Munizzi F, Frascio F, Pugliese V, Truini M: Detection of tissue abnormalities in normal mucosa surrounding colorectal cancer using an endocytoscopy system. Endoscopy; 2007 Apr;39(4):369-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of tissue abnormalities in normal mucosa surrounding colorectal cancer using an endocytoscopy system.
  • In one surgical specimen obtained after resection of a cancer of the transverse colon, focal abnormalities of colonic glands were detected 7 cm away from the primary tumor, within macroscopically normal mucosa.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Endoscopy, Gastrointestinal / methods. Intestinal Mucosa / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427076.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Choi PW, Kim CN, Chang SH, Chang WI, Kim CY, Choi HM: Cardiac metastasis from colorectal cancer: a case report. World J Gastroenterol; 2009 Jun 7;15(21):2675-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastasis from colorectal cancer: a case report.
  • We report a case of cardiac metastasis from colorectal cancer.
  • A 70-year-old woman was referred with a presumptive diagnosis of sigmoid colon cancer with cardiac myxoma.
  • The patient underwent anterior resection for sigmoid colon cancer (T4N2).
  • Histological examination revealed adenocarcinoma, which was identical to the primary lesion.
  • Although two-dimensional echocardiography has become the diagnostic test of choice for detecting cardiac tumors, in patients with colorectal cancer showing a cardiac mass, further diagnostic evaluation such as a magnetic resonance imaging might be necessary.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cardiol. 1999 Nov;22(11):749 [10554692.001]
  • [Cites] J Gastrointest Surg. 2008 May;12(5):981-2 [17939014.001]
  • [Cites] Tex Heart Inst J. 2001;28(3):215-7 [11678259.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2003 Jul;51(7):330-2 [12892468.001]
  • [Cites] Am Heart J. 1982 Sep;104(3):637-8 [7113905.001]
  • [Cites] J Am Coll Cardiol. 1985 Dec;6(6):1422-7 [3864856.001]
  • [Cites] AJR Am J Roentgenol. 1986 May;146(5):907-18 [3515882.001]
  • [Cites] Arch Pathol Lab Med. 1986 May;110(5):371-4 [3516115.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):195-201 [3411785.001]
  • [Cites] J Thorac Imaging. 1989 Apr;4(2):58-64 [2716078.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1456-9 [2306690.001]
  • [Cites] N Engl J Med. 1992 Nov 12;327(20):1442-8 [1328882.001]
  • [Cites] Tex Heart Inst J. 1993;20(4):296-8 [8298329.001]
  • [Cites] Acta Cardiol. 1994;49(2):191-6 [8053287.001]
  • [Cites] Changgeng Yi Xue Za Zhi. 1996 Sep;19(3):264-7 [8921646.001]
  • [Cites] Acta Med Port. 1997 Apr;10(4):331-4 [9341033.001]
  • [Cites] AMA Arch Pathol. 1951 Jan;51(1):98-128 [14789340.001]
  • [Cites] AMA Arch Intern Med. 1953 Feb;91(2):224-49 [13016041.001]
  • [Cites] J Am Med Assoc. 1953 Oct 24;153(8):712-5 [13096280.001]
  • [Cites] Circulation. 1960 Sep;22:474-83 [13711211.001]
  • [Cites] Ital Heart J. 2005 Sep;6(9):778-81 [16212084.001]
  • [Cites] J Laryngol Otol. 2005 Oct;119(10):834-6 [16259667.001]
  • [Cites] Surg Today. 2000;30(1):74-7 [10648089.001]
  • (PMID = 19496202.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2691503
  •  go-up   go-down


64. Osunkoya AO, Netto GJ, Epstein JI: Colorectal adenocarcinoma involving the prostate: report of 9 cases. Hum Pathol; 2007 Dec;38(12):1836-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal adenocarcinoma involving the prostate: report of 9 cases.
  • We present 9 consult cases, the largest series to date, of colorectal adenocarcinoma involving the prostate.
  • Three cases were diagnosed before biopsy of the colon, which led to the discovery of a primary colonic tumor.
  • The mean interval between the detection of the primary colonic tumor and prostatic involvement in the other 6 cases was 30 months (range, 1-52 months).
  • Two cases involved the prostate after the recurrence of rectal adenocarcinoma at the anastomotic site of the previous colonic resection.
  • There are critical therapeutic and prognostic implications for distinguishing between prostatic adenocarcinoma and colorectal carcinoma involving the prostate.
  • Colorectal adenocarcinoma should be considered on prostate sampling when carcinoma exhibits either "dirty" necrosis, tall columnar epithelium with mucin production, mucin-positive signet-ring cells, villous architecture, or associated inflammation.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Prostatic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868775.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


65. Ruan WJ, Lin J, Xu EP, Xu FY, Ma Y, Deng H, Huang Q, Lv BJ, Hu H, Cui J, Di MJ, Dong JK, Lai MD: IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B; 2006 Nov;7(11):929-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulin-like growth factor binding-protein-7 (IGFBP7) was obtained from our previous colonic adenocarcinoma (CRC) and normal mucosa suppression subtraction hybridization (SSH) cDNA libraries.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. DNA Methylation. Insulin-Like Growth Factor Binding Proteins / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2001 Oct;54(5):285-8 [11577168.001]
  • [Cites] Int J Cancer. 2001 Jul 20;95(4):216-22 [11400113.001]
  • [Cites] Cell Growth Differ. 2002 May;13(5):205-13 [12065244.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3410-5 [12624183.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2043-51 [12894577.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7717-23 [14633696.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):141-8 [15027891.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6789-95 [15501955.001]
  • [Cites] Cell Growth Differ. 1993 Sep;4(9):715-22 [7694637.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12981-6 [9371786.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1283-7 [10199768.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2370-5 [10344746.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2787-90 [10383131.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):109-17 [10623583.001]
  • [Cites] Mol Med. 2000 Feb;6(2):126-35 [10859029.001]
  • [Cites] World J Gastroenterol. 2001 Oct;7(5):726-31 [11819864.001]
  • (PMID = 17048309.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Tumor Suppressor Proteins; 0 / insulin-like growth factor binding protein-related protein 1
  • [Other-IDs] NLM/ PMC1635813
  •  go-up   go-down


66. Yi JY, Jung YJ, Choi SS, Chung E: TNF-alpha downregulates E-cadherin and sensitizes response to γ-irradiation in Caco-2 cells. Cancer Res Treat; 2009 Sep;41(3):164-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The purpose of the present study was to assess the biological effects of TNF-alpha in Caco-2 well-differentiated colon adenocarcinoma cells and to determine radiation sensitivity in order to develop TNF-alpha into a cancer therapeutic agent.
  • CONCLUSION: These results suggest that TNF-alpha might be potentially applied as a therapeutic agent in order to enhance sensitivity to 2 Gy of γ-irradiation administered in radiotherapy for the treatment of human colon cancer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 1999 Jan;112 ( Pt 1):137-46 [9841910.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):99-104 [16112667.001]
  • [Cites] Int J Cancer. 1993 Mar 12;53(5):829-36 [8449608.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6743-59 [15273737.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):314-20 [15251122.001]
  • [Cites] Exp Cell Res. 2004 Jan 1;292(1):29-39 [14720504.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1352-7 [14520471.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3526-34 [12972530.001]
  • [Cites] Nat Rev Drug Discov. 2003 Sep;2(9):736-46 [12951580.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3687-700 [12890751.001]
  • [Cites] Cell. 2003 Jul 25;114(2):181-90 [12887920.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):458-67 [12879461.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):429-37 [12850194.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25461-7 [12707267.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13153-9 [11278357.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 May;280(5):L914-22 [11290515.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5680-9 [10891504.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1778(3):660-9 [17854762.001]
  • [Cites] Clin Immunol. 2008 Jan;126(1):67-80 [17964857.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7703-17 [17785436.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Dec;291(6):L1232-45 [16891393.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1606-14 [10197636.001]
  • (PMID = 19809566.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2757662
  • [Keywords] NOTNLM ; Bcl-xl / Caco-2 cells / Claudin-4 / E-cadherin / Radio-sensitivity / TNF-alpha
  •  go-up   go-down


67. Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY: Mucinous carcinoma in Crohn's disease originating in a fistulous tract. World J Gastrointest Oncol; 2010 Jul 15;2(7):307-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although fistula cancer is rarely described in Crohn's disease, use of immunosuppressant and biological agents may play an initiating or exacerbating role in its development or progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160662.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999135
  • [Keywords] NOTNLM ; Adalimumab / Anal fistula / Anorectal adenocarcinoma / Crohn’s disease / Fistula carcinoma / Infliximab / Tumor necrosis factor antibodies
  •  go-up   go-down


68. Fung AY, Enke CA, Ayyangar KM, Thompson RB, Zhen W, Raman NV, Djajaputra D, Li S, Nehru RM, Pillai S, Sourivong P, Headley M, Yager AL: Effects of field parameters on IMRT plan quality for gynecological cancer: a case study. J Appl Clin Med Phys; 2005;6(3):46-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of field parameters on IMRT plan quality for gynecological cancer: a case study.
  • Traditional external beam radiotherapy of gynecological cancer consists of a 3D, four-field-box technique.
  • This is a case report of IMRT planning for a patient with endometrial cancer.
  • Delineated anatomical contours included the intrapelvic nodes (PTV), bone marrow, small bowel, bladder, rectum, sigmoid colon, periaortic nodes (PTV), spinal cord, left kidney, right kidney, large bowel, liver, and tissue (excluding the PTVs).
  • Compared with the 3D plan, the IMRT plan had superior dose conformity and spared the bladder and sigmoid colon embedded in the intrapelvic nodes.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143791.001).
  • [ISSN] 1526-9914
  • [Journal-full-title] Journal of applied clinical medical physics
  • [ISO-abbreviation] J Appl Clin Med Phys
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Salas-Valverde S, Lizano A, Gamboa Y, Vega S, Barrantes M, Santamaría S, Zamora JB: Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases. Pediatr Surg Int; 2009 Dec;25(12):1073-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases.
  • BACKGROUND: Carcinoma of the colon and rectum is rare in the pediatric age group, and usually presents with an advanced stage disease bearing a poor prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Antineoplastic Agents / therapeutic use. Colectomy / methods. Colonic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):39-41 [15654277.001]
  • [Cites] Cancer. 1958 Jul-Aug;11(4):855-7 [13561255.001]
  • [Cites] Surg Gynecol Obstet. 1962 Apr;114:438-42 [13898554.001]
  • [Cites] J Pediatr Surg. 1976 Dec;11(6):967-71 [1003308.001]
  • [Cites] Clin Genet. 1987 Jan;31(1):35-44 [3568432.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] Pediatrics. 1963 Oct;32:558-71 [14069097.001]
  • [Cites] J Chemother. 2002 Jun;14(3):301-8 [12120887.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1085-9; discussion 1089-90 [1403541.001]
  • [Cites] Eur J Pediatr Surg. 2003 Feb;13(1):66-8 [12664421.001]
  • [Cites] Dis Colon Rectum. 1976 Sep;19(6):529-34 [183939.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):338-41 [11719875.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):952-5 [4016687.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1322-6 [3971300.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):919-21 [1640344.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1188-93 [8308690.001]
  • [Cites] Arch Surg. 1970 Apr;100(4):527-31 [4190476.001]
  • [Cites] Dis Colon Rectum. 1981 Jan-Feb;24(1):25-8 [7472098.001]
  • [Cites] Surgery. 1983 Mar;93(3):409-14 [6600855.001]
  • [Cites] Am J Surg. 1958 Jul;96(1):47-53 [13545485.001]
  • [Cites] Surg Gynecol Obstet. 1974 Feb;138(2):169-70 [4810853.001]
  • [Cites] Br J Surg. 1984 Apr;71(4):272-7 [6704677.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1560-2 [14605580.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2464-72 [200342.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):209-11 [17255833.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Pediatr Surg. 1989 Nov;24(11):1189-91 [2553912.001]
  • [Cites] South Med J. 1976 Jan;69(1):24-7 [1246645.001]
  • (PMID = 19816697.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Tompkins LM, Li H, Li L, Lynch C, Xie Y, Nakanishi T, Ross DD, Wang H: A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol; 2010 Dec 01;80(11):1754-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Induction of the breast cancer resistance protein (BCRP/ABCG2) expression has been found in various tissues and cell-types after exposure to chemicals including 17β-estradiol, rosiglitazone, imatinib, as well as aryl hydrocarbon receptor (AhR) activators such as 2,3,7,8-tetrachlorodibenzodioxin, 3-methylcholanthrene (3MC), and omeprazole.
  • Here, we demonstrate the AhR-dependent induction of ABCG2 expression in human colon adenocarcinoma LS174T cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer Res. 2005 Jan 15;65(2):596-604 [15695404.001]
  • [Cites] Mol Pharmacol. 1999 Oct;56(4):784-90 [10496962.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):747-52 [15970668.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1754-63 [15917307.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 May;290(5):E798-807 [16352672.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23812-23 [16785230.001]
  • [Cites] Curr Opin Pharmacol. 2006 Oct;6(5):528-32 [16899406.001]
  • [Cites] Drug Metab Dispos. 2006 Oct;34(10):1756-63 [16837569.001]
  • [Cites] Toxicol Sci. 2007 Apr;96(2):227-36 [17077187.001]
  • [Cites] Br J Pharmacol. 2007 May;151(2):163-74 [17375082.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Jul 15;230(2):252-60 [18433817.001]
  • [Cites] Pharm Res. 2009 Apr;26(4):872-82 [19034627.001]
  • [Cites] Toxicol Sci. 2009 Oct;111(2):238-46 [19474220.001]
  • [Cites] Mol Pharm. 2009 Nov-Dec;6(6):1631-43 [19874004.001]
  • [Cites] Mol Pharmacol. 2010 Aug;78(2):175-85 [20460431.001]
  • [Cites] Hepatology. 2001 May;33(5):1232-8 [11343253.001]
  • [Cites] Arch Biochem Biophys. 2000 Jan 1;373(1):163-74 [10620335.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3458-64 [11309308.001]
  • [Cites] Biochim Biophys Acta. 2001 Sep 21;1520(3):234-41 [11566359.001]
  • [Cites] Stem Cells. 2002;20(1):11-20 [11796918.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2943-50 [12089223.001]
  • [Cites] Curr Protein Pept Sci. 2002 Oct;3(5):503-11 [12369998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4150-5 [12644700.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15001-6 [12566446.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4048-54 [12874005.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1247-51 [14973083.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24218-25 [15044468.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8185-9 [1325649.001]
  • [Cites] Mol Pharmacol. 1993 Apr;43(4):504-8 [8386305.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:307-40 [7598497.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43 [9391166.001]
  • [Cites] Arch Biochem Biophys. 1998 Sep 1;357(1):155-63 [9721195.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70 [9861027.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5707-12 [9865727.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):993-1000 [15882976.001]
  • (PMID = 20804740.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK061652; United States / NIDDK NIH HHS / DK / R01 DK061652-08; United States / NIDDK NIH HHS / DK / DK061652
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / AHR protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Neoplasm Proteins; 0 / Plant Extracts; 0 / Receptors, Aryl Hydrocarbon; 0 / Xenobiotics; 19FUJ2C58T / Ginkgo biloba extract; 56-49-5 / Methylcholanthrene
  • [Other-IDs] NLM/ NIHMS238169; NLM/ PMC2958249
  •  go-up   go-down


71. Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS: Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol; 2005 Sep 15;162(6):548-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites.
  • African Americans have the highest colon cancer incidence and mortality rates among all US ethnic groups.
  • Epidemiologic studies suggest that use of nonsteroidal antiinflammatory drugs (NSAIDs) is associated with a reduced risk of colon cancer, but no study to date with adequate sample size has reported on the association among African Americans.
  • The authors examined the association between NSAID use and risk of colon cancer in a population-based, case-control study in North Carolina that enrolled 731 African-American (294 cases, 437 controls) and 960 White (349 cases, 611 controls) participants between 1996 and 2000.
  • Odds ratios were calculated using unconditional logistic regression for categories of NSAIDs and colon cancer risk.
  • Inverse associations between regular NSAID use and colon cancer were similar for African Americans (odds ratio = 0.41, 95% confidence interval: 0.22, 0.77) and Whites (odds ratio = 0.48, 95% confidence interval: 0.28, 0.83) but stronger for women than men.
  • These results add new knowledge suggesting that the protective effect of NSAIDs against colon cancer is similar among African Americans and Whites.
  • [MeSH-major] Adenocarcinoma / ethnology. African Americans. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Colonic Neoplasms / ethnology. European Continental Ancestry Group

  • MedlinePlus Health Information. consumer health - African American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093288.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA66635; United States / NCI NIH HHS / CA / T32-CA09330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


72. Cellini C, Hunt SR, Fleshman JW, Birnbaum EH, Bierhals AJ, Mutch MG: Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor? World J Surg; 2010 May;34(5):1102-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?
  • BACKGROUND: Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases.
  • We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all.
  • METHODS: Patients with metastatic rectal cancer to liver were identified from a colorectal cancer database from 2002 to 2008.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1269-76 [17318552.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):592-8 [18936572.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2283-92 [12436433.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5910-7 [19018087.001]
  • [Cites] Ann Surg Oncol. 2009 Jan;16(1):35-41 [18987915.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Oncologist. 1999;4(3):197-208 [10394588.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1829-35 [18662955.001]
  • (PMID = 20177683.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Su YC, Hsu YC, Chai CY: Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci; 2006 Jan;22(1):14-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma.
  • Thyroid transcription factor-1 (TTF-1), and cytokeratin 7 (CK7) and cytokeratin 20 (CK20) have recently been reported to be useful to distinguish between primary and metastatic lung adenocarcinoma.
  • The aim of this study was to determine the usefulness of the staining patterns of pulmonary adenocarcinoma with antibodies to TTF-1, CK7, and CK20 in differentiating primary from metastatic pulmonary adenocarcinoma.
  • Of the 66 lung adenocarcinoma specimens that were enrolled in our study, there were 40 primary lung adenocarcinomas, 12 metastatic adenocarcinomas from breast, 13 metastatic adenocarcinomas from colon, and 1 metastatic adenocarcinoma from stomach.
  • We found that 73% of primary lung adenocarcinomas expressed TTF-1, whereas all nonpulmonary adenocarcinomas lacked TTF-1 staining.
  • CK7 expression was significantly more frequent in adenocarcinomas of pulmonary and breast origin than gastrointestinal (GI) origin (p < 0.001).
  • In contrast, CK20 expression was significantly more prevalent in adenocarcinoma that originated in the GI tract than that of pulmonary or breast origin (p < 0.001).
  • A combination of TTF-1+CK7+CK20- was highly significantly associated with primary adenocarcinoma of lung (vs GI tract, p < 0.001; vs breast, p < 0.001).
  • A combination of TTF-1-CKCK20+ was highly significantly associated with adenocarcinoma of GI origin (vs lung, p < 0.001; vs breast, p < 0.001).
  • Our study has confirmed that expression of CK7, CK20, and TTF-1 is a useful immunohistochemical marker for diagnosis of lung tumors and for differential diagnosis of primary pulmonary adenocarcinomas from extrapulmonary adenocarcinomas metastatic to the lung.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Keratins / analysis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570563.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  •  go-up   go-down


74. Pajak B, Orzechowski A: Ethylenediaminetetraacetic acid affects subcellular expression of clusterin protein in human colon adenocarcinoma COLO 205 cell line. Anticancer Drugs; 2007 Jan;18(1):55-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethylenediaminetetraacetic acid affects subcellular expression of clusterin protein in human colon adenocarcinoma COLO 205 cell line.
  • The aim of our study was to determine the expression of various isoforms of clusterin and to evaluate how etoposide or calcium chelators [ethylenediaminetetraacetic acid and (2-aminoethoxyethane)-N,N,N',N'-tetraacetic acid] affect the subcellular expressions of the 50-kDa isoform of clusterin protein in colon adenocarcinoma COLO 205 cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Antineoplastic Agents, Phytogenic / pharmacology. Calcium / metabolism. Cell Survival / drug effects. Chelating Agents / pharmacology. Clusterin / pharmacology. Colorectal Neoplasms / metabolism. Edetic Acid / pharmacology. Etoposide / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159503.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Chelating Agents; 0 / Clusterin; 0 / Protein Isoforms; 6PLQ3CP4P3 / Etoposide; 9G34HU7RV0 / Edetic Acid; SY7Q814VUP / Calcium
  •  go-up   go-down


75. Nazaruk J, Karna E, Wieczorek P, Sacha P, Tryniszewska E: In vitro antiproliferative and antifungal activity of essential oils from Erigeron acris L. and Erigeron annuus (L.) Pers. Z Naturforsch C; 2010 Nov-Dec;65(11-12):642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cell viability assay was performed in cultured fibroblasts, cancer cell lines (MCF-7 and MDA-MBA-231), and endometrial adenocarcinoma (Ishikawa) cells as well as colon adenocarcinoma (DLD-1) cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
  • The data presented suggest that essential oils from E. acris and E. annuus possess antifungal activity against Candida spp. and antiproliferative activity against breast cancer MCF-7 cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319704.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Oils, Volatile
  •  go-up   go-down


76. Shon YH, Nam KS: Chemopreventive effect of protein extract of Asterina pectinifera in HT-29 human colon adenocarcinoma cells. Arch Pharm Res; 2006 Mar;29(3):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive effect of protein extract of Asterina pectinifera in HT-29 human colon adenocarcinoma cells.
  • We investigated the effect of protein extract of Asterina pectinifera on the activity of 4 enzymes that may play a role in adenocarcinoma of the colon: quinone reductase (QR), glutathione S-transferase (GST), ornithine decarboxylase (ODC), and cyclooxygenase (COX)-2.
  • QR and GST activity increased in HT-29 human colon adenocarcinoma cells increased that had been exposed to 4 concentrations of the protein extract (80, 160, 200, and 240 microg/mL).
  • These results suggest that this protein extract of A pectinifera has chemopreventive activity in HT-29 human colon adenocarcinoma cells, and therefore, may have the potential to function as a chemopreventive agent in human colorectal cancer.
  • [MeSH-minor] Adenocarcinoma. Colonic Neoplasms. Cyclooxygenase 2 / metabolism. Dose-Response Relationship, Drug. Glutathione Transferase / metabolism. Humans. NAD(P)H Dehydrogenase (Quinone) / metabolism. Ornithine Decarboxylase / metabolism. Ornithine Decarboxylase Inhibitors. Tetradecanoylphorbol Acetate

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596993.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Ornithine Decarboxylase Inhibitors; 0 / Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 2.5.1.18 / Glutathione Transferase; EC 4.1.1.17 / Ornithine Decarboxylase; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


77. Okada K, Shatari T, Sasaki T, Tamada T, Suwa T, Furuuchi T, Takenaka Y, Hori M, Sakuma M: Is histopathological evidence really essential for making a surgical decision about mucinous carcinoma arising in a perianal fistula? Report of a case. Surg Today; 2008;38(6):555-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an unusual case of mucinous adenocarcinoma of the anus associated with a chronic anal fistula, treated successfully by abdominoperineal resection (APR).
  • Although multiple biopsies failed to reveal any histological evidence of malignancy, cancer was diagnosed from the mucin obtained for cytology.
  • Subsequent histological examination of the resected specimen revealed clusters of cancer cells floating in a mucous lake, suggesting that it would have been difficult to acquire the cells in a biopsy sample.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Rectal Fistula / complications

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1966 Sep-Oct;9(5):371-6 [5958587.001]
  • [Cites] Tech Coloproctol. 2006 Mar;10(1):51-3 [16528482.001]
  • [Cites] Hum Pathol. 1981 Nov;12(11):1034-7 [6274783.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Endoscopy. 1997 May;29(4):335 [9255549.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1511-2 [9407995.001]
  • [Cites] Postgrad Med J. 1987 Jun;63(740):503-4 [2829151.001]
  • [Cites] Chir Ital. 1999 Sep-Oct;51(5):413-6 [10738618.001]
  • [Cites] Ir Med J. 1984 Oct;77(10):326 [6094391.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s138-40 [15655599.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):562-6 [6271516.001]
  • [Cites] Am J Surg. 1948 Feb;75(2):285-9 [18907412.001]
  • [Cites] Tech Coloproctol. 2006 Oct;10 (3):249-52 [16969607.001]
  • [Cites] Med J Malaysia. 2006 Mar;61(1):88-90 [16708740.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Apr;98(4):310-2 [16792461.001]
  • [Cites] Histopathology. 1984 Mar;8(2):279-92 [6327491.001]
  • [Cites] Acta Pathol Jpn. 1984 May;34(3):649-54 [6087605.001]
  • [Cites] Mil Med. 1986 Oct;151(10):543-6 [3022189.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1163-5 [1682590.001]
  • [Cites] Am Surg. 2003 Feb;69(2):166-9 [12641361.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • (PMID = 18516539.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


78. Ma YM, Wu BP, Xia OD: [Expression and significance of interferon-inducible transmembrane protein-1 gene in Peutz-Jeghers syndrome]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):541-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Reverse transcription-PCR was employed to detect the mRNA expression of IFITM1 in 16 PJS polyp samples, adenomatous polyp tissues, colon adenocarcinoma samples, and normal intestinal mucosal tissues.
  • RESULTS: The IFITM1 mRNA expression was detected in all these tissues, and the expression intensity increased in the order of normal intestinal mucosa, PJS polyp, adenomatous polyp, and colon adenocarcinoma (F=92.704, P=0.000).

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304549.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / leu-13 antigen
  •  go-up   go-down


79. Friedman S: Cancer in Crohn's disease. Gastroenterol Clin North Am; 2006 Sep;35(3):621-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer in Crohn's disease.
  • When each of these studies is scrutinized, however, there is only enough evidence to support a link between colorectal adenocarcinoma, SBA, and squamous and adenocarcinomas that are associated with perianal fistulizing disease.
  • All of the studies of large bowel adenocarcinoma or SBA follow patients in an era during which there were far fewer effective medicines to treat CD and surgery was more commonplace.
  • The only surveillance study of patients who had extensive, long-duration Crohn's colitis showed a 22% risk for developing neoplasia (low-grade, high-grade, or cancer) after four surveillance examinations.
  • Overall results from this study and the multitude of the other studies show that the risk for cancer in Crohn's colitis is equal to that in UC given equal extent and duration of disease.
  • Patients who have Crohn's colitis that affects at least one third of the colon and with at least 8 years of disease should undergo screening and surveillance, just as in UC.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952744.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 102
  •  go-up   go-down


80. Harada O, Suga T, Suzuki T, Nakamoto K, Kobayashi M, Nomiyama T, Nadano D, Ohyama C, Fukuda MN, Nakayama J: The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer. Int J Cancer; 2007 Sep 1;121(5):1072-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer.
  • Here, we report that trophinin is expressed in tumors from 64% of colon cancer patients (n = 50) and high trophinin expression is closely associated with poor prognosis.
  • To determine the link between trophinin expression and malignancy, colon adenocarcinoma SW480 cells were stably transfected with trophinin.
  • Immunohistochemical analysis of tumors from the colorectal cancer patients confirmed positive correlation of HMGB1 protein expression in the nucleus to trophinin expression in tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Adhesion Molecules / physiology. Colorectal Neoplasms / pathology. Neoplasm Invasiveness. Trophoblasts / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17487845.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD 34108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / BYSL protein, human; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / DNA, Complementary; 0 / HMGB1 Protein; 0 / Receptors, Immunologic; 0 / TRO protein, human; 0 / TROAP protein, human
  •  go-up   go-down


81. Patel AA, Gupta D, Seligson D, Hattab EM, Balis UJ, Ulbright TM, Kohane IS, Berman JJ, Gilbertson JR, Dry S, Schirripa O, Yu H, Becich MJ, Parwani AV, Shared Pathology Informatics Network: Availability and quality of paraffin blocks identified in pathology archives: a multi-institutional study by the Shared Pathology Informatics Network (SPIN). BMC Cancer; 2007 Feb 28;7:37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each site generated a list of 100 common tumor cases (25 cases each of breast adenocarcinoma, colonic adenocarcinoma, lung squamous carcinoma, and prostate adenocarcinoma) and 100 rare tumor cases (25 cases each of adrenal cortical carcinoma, gastro-intestinal stromal tumor [GIST], adenoid cystic carcinoma, and mycosis fungoides) using a combination of Tumor Registry, laboratory information system (LIS) and/or SPIN-related tools.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1843-9 [11448894.001]
  • [Cites] Mol Diagn. 2000 Dec;5(4):287-99 [11172493.001]
  • [Cites] Arch Pathol Lab Med. 1996 Oct;120(10):909-12 [12046602.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):870-6 [12472280.001]
  • [Cites] AMIA Annu Symp Proc. 2003;:584-8 [14728240.001]
  • [Cites] AMIA Annu Symp Proc. 2003;:937 [14728442.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):176-86 [14983930.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1115-9 [15026787.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4614-21 [15269132.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 1):607-10 [15360884.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 1):663-7 [15360896.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 2):1264-7 [15361017.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):1-3 [8646703.001]
  • [Cites] Urology. 1996 Nov;48(5):773-7 [8911524.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1065-76 [9870854.001]
  • [Cites] Science. 1998 Dec 18;282(5397):2165-6 [9890818.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):202-8 [9917130.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):296-300 [10320140.001]
  • [Cites] Clin Lab Med. 2004 Dec;24(4):913-43, vi [15555749.001]
  • [Cites] BMC Cancer. 2005;5:108 [16111498.001]
  • [Cites] BMC Med Inform Decis Mak. 2006;6:12 [16515714.001]
  • [Cites] AMIA Annu Symp Proc. 2005;:515-9 [16779093.001]
  • [Cites] BMC Cancer. 2006;6:120 [16677389.001]
  • [Cites] Community Genet. 1999;2(2-3):51-60 [11787507.001]
  • (PMID = 17386082.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA091343; United States / NCI NIH HHS / CA / U01 CA091429; United States / NCI NIH HHS / CA / U01CA091429; United States / NCI NIH HHS / CA / P30 CA016042; United States / NCI NIH HHS / CA / U01 CA091343; United States / NCI NIH HHS / CA / UO1CA91338-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1810540
  •  go-up   go-down


82. Mellor HR, Ferguson DJ, Callaghan R: A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer; 2005 Aug 8;93(3):302-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The quiescent cell population of tumours poses a barrier to the success of many cancer therapies.
  • Based on the multicellular tumour spheroid model, a system was developed using human colon adenocarcinoma (DLD-1) cells to mimic the microenvironment of quiescent microregions of solid tumours.
  • In summary, TS(Q) show considerable resistance to a panel of established chemotherapeutic agents and represent a useful model for evaluating the efficacy of drugs and other cancer therapies in quiescent tumours.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):111-5 [12620406.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1706-11 [12670925.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):330-8 [12724731.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4322-6 [12907598.001]
  • [Cites] Biochem Pharmacol. 2003 Oct 15;66(8):1547-54 [14555233.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7265-79 [14576837.001]
  • [Cites] Biochem Pharmacol. 2004 Jan 1;67(1):17-30 [14667925.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):205-11 [14728934.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):253-65 [15057285.001]
  • [Cites] Pharmacol Rev. 2004 Jun;56(2):185-229 [15169927.001]
  • [Cites] Cancer Lett. 2004 Jul 8;210(1):119-24 [15172129.001]
  • [Cites] J Gen Virol. 2004 Oct;85(Pt 10):2925-30 [15448354.001]
  • [Cites] Growth. 1970 Sep;34(3):271-82 [5471822.001]
  • [Cites] J Natl Cancer Inst. 1971 Jan;46(1):113-20 [5101993.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2619-30 [1098765.001]
  • [Cites] J Natl Cancer Inst. 1980 Nov;65(5):885-9 [6933258.001]
  • [Cites] J Urol. 1989 Nov;142(5):1342-6 [2478729.001]
  • [Cites] Adv Enzyme Regul. 1989;29:27-46 [2633613.001]
  • [Cites] Ann N Y Acad Sci. 1993 Nov 30;698:193-203 [8279757.001]
  • [Cites] Cell. 1994 Jul 15;78(1):67-74 [8033213.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1029-32 [7734295.001]
  • [Cites] Trends Biochem Sci. 1995 Oct;20(10):435-9 [8533159.001]
  • [Cites] Nat Med. 1996 Nov;2(11):1204-10 [8898746.001]
  • [Cites] Br J Cancer. 1997;75(2):196-201 [9010026.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1408-16 [9537241.001]
  • [Cites] Clin Cancer Res. 1995 May;1(5):473-80 [9816006.001]
  • [Cites] Cancer Lett. 1998 Sep 11;131(1):29-34 [9839617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):697-9 [9845079.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):313-23 [10027389.001]
  • [Cites] Biochem Pharmacol. 1999 Apr 1;57(7):727-41 [10075079.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):131-41 [10388527.001]
  • [Cites] Radiat Med. 1999 Jul-Aug;17(4):259-64 [10510897.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):193-207 [11033306.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7919-26 [11112789.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):555-9 [11733971.001]
  • [Cites] Exp Cell Res. 2000 Jun 15;257(2):231-7 [10837136.001]
  • (PMID = 16052217.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2361565
  •  go-up   go-down


83. Tsikitis VL, Larson DW, Poola VP, Nelson H, Wolff BG, Pemberton JH, Cima RR: Postoperative morbidity with diversion after low anterior resection in the era of neoadjuvant therapy: a single institution experience. J Am Coll Surg; 2009 Jul;209(1):114-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The use of defunctioning stomas has been advocated to mitigate the adverse sequela from anastomotic dehiscence after rectal cancer resection.
  • STUDY DESIGN: This retrospective case series included patients who were treated with neoadjuvant therapy and had rectal cancer resection with curative intent, from 1996 to 2007.
  • CONCLUSIONS: Low postoperative morbidity after colorectal and coloanal anastomosis for adenocarcinoma is possible in patients who have received neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Ileostomy / methods. Rectal Neoplasms / surgery. Surgical Wound Dehiscence / epidemiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Surg. 2009 Dec;209(6):790-1; author reply 791-2 [19959054.001]
  • (PMID = 19651071.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


84. Sonoda K, Izumi K, Matsui Y, Inomata M, Shiraishi N, Kitano S: Decreased growth rate of lung metastatic lesions after splenectomy in mice. Eur Surg Res; 2006;38(5):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Colon 26 cancer cells were inoculated into the lateral tail vein of 90 mice.
  • [MeSH-minor] Adenocarcinoma / pathology. Animals. Cell Proliferation. Colonic Neoplasms / pathology. Female. Fibroblast Growth Factors / metabolism. Mice. Mice, Inbred BALB C. Neoplasm Metastasis / therapy. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16940732.001).
  • [ISSN] 0014-312X
  • [Journal-full-title] European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes
  • [ISO-abbreviation] Eur Surg Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 0 / fibroblast growth factor 13; 62031-54-3 / Fibroblast Growth Factors
  •  go-up   go-down


85. Hansel DE, Rahman A, Wilentz RE, Shih IeM, McMaster MT, Yeo CJ, Maitra A: HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer; 2005;35(1):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have examined HLA-G expression in a number of human gastrointestinal malignancies, including pancreatic ductal adenocarcinoma, ampullary cancer, biliary cancer, and colorectal cancer by immunolabeling analysis.
  • Across all cancer subtypes, 52-79% of lesions demonstrated expression of HLA-G, with up to 33% of lesions demonstrating diffuse (>75%) expression.
  • In addition, we utilized the neoplastic progression model of colorectal cancer to evaluate HLA-G protein expression in normal colon, tubulovillous adenomas, invasive cancer, and liver metastases arising from colorectal cancer.
  • Focal HLA-G expression was detected in regions of normal colon adjacent to sites of adenomatous and cancerous lesions, as well as in all stages of cancer progression.
  • Overall, the percentage of diffusely (>75%) labeled lesions appeared increased in preneoplastic and neoplastic conditions, as compared to normal colon.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722570.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


86. Morán Y, Valderrama E, Camargo ME, Rivero MB, Chiurillo MA: [Chemiluminescent measurement of telomere DNA content in archival biopsies of colon adenocarcinoma]. Invest Clin; 2007 Dec;48(4):485-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemiluminescent measurement of telomere DNA content in archival biopsies of colon adenocarcinoma].
  • [Transliterated title] Determinación por quimioluminiscencia del contenido de telómero en biopsias de archivo de cáncer de colon.
  • Telomeres shorten with age, which can be associated to genomic instability and to an increment of the risk of suffering from cancer.
  • In this work, a slot blot assay was adapted to quantify the relative content, instead of the length, of telomeric DNA from paraffin-embedded archival specimens of colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Colonic Neoplasms / chemistry. DNA, Neoplasm / analysis. Luminescent Measurements / methods. Nucleic Acid Hybridization / methods. Telomere / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271393.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Venezuela
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA, Neoplasm; 0 / Strep-avidin conjugated horseradish peroxidase; EC 1.11.1.- / Horseradish Peroxidase
  •  go-up   go-down


87. Yaoita H, Ohkawara H, Uekita H, Mitsugi M, Tajima H, Kaneko H, Hoshino Y, Otani S, Gotoh M, Maruyama Y: Low serum ferritin levels as a clue to colonic cancer detection in two patients with coronary artery disease: a case report. Fukushima J Med Sci; 2005 Dec;51(2):95-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low serum ferritin levels as a clue to colonic cancer detection in two patients with coronary artery disease: a case report.
  • We diagnosed colonic cancer using low serum ferritin levels as a clue in two patients with cardiac or cardiopulmonary disease.
  • In both patients, PET documented abnormal tracer accumulation in the colon.
  • A colonic adenocarcinoma was detected at the site of the positive PET finding in each patient.
  • Both patients underwent curative resection of the cancer.
  • The detection of the levels of serum ferritin may be available for the screening colonic cancer in patients declining colonoscopic examination.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Coronary Artery Disease / complications. Ferritins / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Aged. Colonoscopy. Humans. Male. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555630.001).
  • [ISSN] 0016-2590
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9007-73-2 / Ferritins
  •  go-up   go-down


88. Kuester D, Dalicho S, Mönkemüller K, Benedix F, Lippert H, Guenther T, Roessner A, Meyer F: Synchronous multifocal colorectal carcinoma in a patient with delayed diagnosis of ulcerative pancolitis. Pathol Res Pract; 2008;204(12):905-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with ulcerative colitis face an increased lifetime risk of developing colorectal cancer.
  • Histology of the colonic biopsies showed active ulcerative pancolitis with extensive multifocal low- and high-grade dysplasia.
  • In the resection specimen, four clinically unsuspected, partly mucinous adenocarcinomas accompanied by several foci of low- and high-grade dysplasia were found in the left colon and rectum.
  • [MeSH-major] Adenocarcinoma / pathology. Colitis, Ulcerative / complications. Colitis, Ulcerative / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Zentralbl Chir. 2015 Dec;140(6):624-6 [25076166.001]
  • (PMID = 18842350.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Gulubova M, Vlaykova T: Chromogranin A-, serotonin-, synaptophysin- and vascular endothelial growth factor-positive endocrine cells and the prognosis of colorectal cancer: an immunohistochemical and ultrastructural study. J Gastroenterol Hepatol; 2008 Oct;23(10):1574-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromogranin A-, serotonin-, synaptophysin- and vascular endothelial growth factor-positive endocrine cells and the prognosis of colorectal cancer: an immunohistochemical and ultrastructural study.
  • BACKGROUND AND AIM: Endocrine differentiation in colorectal adenocarcinoma has been reported but its significance as a prognostic marker remains uncertain.
  • The aim of the present study was to analyze the prognostic significance of endocrine differentiation in colorectal cancer.
  • Ultrastructurally, EC in the tumor tissue displayed some features different from those in the normal colon.
  • CONCLUSIONS: Endocrine differentiation is not an uncommon event in primary colorectal cancer and it could be a useful marker for a worse prognosis after the surgical therapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18771509.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 333DO1RDJY / Serotonin
  •  go-up   go-down


90. Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y: Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos; 2005 Apr;33(4):547-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
  • Continuous use of St. John's wort decreases the bioavailabilities of a variety of drugs.
  • In this study, we aimed to examine the chronic effects of St. John's wort and its constituents, hyperforin and hypericin, on the expression and function of P-glycoprotein in an intestinal cell line, LS 180.
  • We also examined the acute inhibitory effect of St. John's wort on P-glycoprotein by using LLC-GA5-COL150 cells, which overexpress P-glycoprotein. St. John's wort and hyperforin but not hypericin increased the expression of P-glycoprotein in LS 180 cells.
  • Removal of St. John's wort resulted in a restoration of P-glycoprotein level within 48 h.
  • The content of hyperforin in St. John's wort extract was high enough to induce P-glycoprotein, suggesting that the induction of P-glycoprotein by St. John's wort can be almost attributable to hyperforin.
  • The LS 180 cells chronically exposed to St. John's wort or hyperforin exhibited the increase in the function of P-glycoprotein assessed by the efflux of digoxin, and the activities correlated well with P-glycoprotein level.
  • On the other hand, St. John's wort and its two constituents did not show any acute effect on P-glycoprotein-mediated transport of digoxin. St. John's wort induced P-glycoprotein in vitro that functions as a drug efflux pump.
  • Hyperforin is considered to be a primary cause of the inductive effect of St. John's wort.
  • Long-term administration of St. John's wort may cause clinically significant decrease in the plasma concentrations of P-glycoprotein substrates.
  • [MeSH-minor] Adenocarcinoma. Animals. Biological Transport. Cell Line, Tumor. Colonic Neoplasms. Digoxin / metabolism. Humans. LLC-PK1 Cells. Plant Extracts / chemistry. Plant Extracts / pharmacology. Rifampin / pharmacology. Swine. Transfection

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYPERFORIN .
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. PERYLENE .
  • Hazardous Substances Data Bank. DIGOXIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15640377.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bicyclo Compounds; 0 / P-Glycoprotein; 0 / Plant Extracts; 0 / Terpenes; 5QD5427UN7 / Perylene; 73K4184T59 / Digoxin; 7V2F1075HD / hypericin; DHD7FFG6YS / Phloroglucinol; RM741E34FP / hyperforin; VJT6J7R4TR / Rifampin
  •  go-up   go-down


91. Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M: Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer; 2006 Oct 9;95(7):889-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology.
  • Whether peroxisome proliferator-activated receptor (PPAR) delta is a good target for the chemoprevention and/or treatment of colorectal cancer (CRC) remains controversial.
  • In cancer tissues, the PPARdelta protein was accumulated only in those cancer cells with highly malignant morphology, as represented by a large-sized nucleus, round-shaped nucleus, and presence of clear nucleoli.
  • Interestingly, the cancer tissue often contained both PPARdelta-positive and -negative areas, each retaining their respective specific morphological features.
  • Moreover, this pattern persisted even when PPARdelta-positive and -negative cells were aligned next to each other within a single cancer nest or gland and was present in the majority of CRC cases.
  • Peroxisome proliferator-activated receptor delta may have a supporting role in tumorigenesis, and the close association between PPARdelta expression and malignant morphology of CRC cells suggests a pivotal role in cancer tissue.
  • [MeSH-major] Adenocarcinoma / enzymology. Cell Transformation, Neoplastic / pathology. Colorectal Neoplasms / enzymology. PPAR delta / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Recent Prog Horm Res. 1999;54:345-67; discussion 367-8 [10548883.001]
  • [Cites] Cell. 1999 Oct 29;99(3):335-45 [10555149.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1944-51 [10570417.001]
  • [Cites] J Med Chem. 2000 Feb 24;43(4):527-50 [10691680.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1229-38 [10778945.001]
  • [Cites] Nature. 2000 May 25;405(6785):421-4 [10839530.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3043-50 [10850455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80 [11087869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2598-603 [11226285.001]
  • [Cites] J Cell Biol. 2001 Aug 20;154(4):799-814 [11514592.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2239-48 [11733373.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):303-8 [11756685.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3282-8 [12036946.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):721-33 [12419217.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1748-51 [12702555.001]
  • [Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):556-71 [12891558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9968-73 [12909723.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):257-65 [12943711.001]
  • [Cites] Nat Med. 2004 Mar;10(3):245-7 [14758356.001]
  • [Cites] Nat Med. 2004 May;10(5):481-3 [15048110.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3162-70 [15126355.001]
  • [Cites] Trends Pharmacol Sci. 2004 Jun;25(6):331-6 [15165749.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):285-95 [15380519.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Anal Quant Cytol Histol. 1990 Jun;12(3):172-6 [2369470.001]
  • [Cites] Dis Colon Rectum. 1991 Mar;34(3):249-59 [1999132.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1147-56 [8001151.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1567-76 [8623925.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Diabetes. 1998 Apr;47(4):507-14 [9568680.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):103-15 [9926925.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):386-92 [10223762.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1561-74 [10385625.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8992-6 [15480419.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1512-5 [15539957.001]
  • [Cites] Pharmacogenet Genomics. 2005 Oct;15(10):713-21 [16141797.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):3781-9 [16309164.001]
  • [Cites] Pharmacogenet Genomics. 2006 Jan;16(1):43-50 [16344721.001]
  • [Cites] Carcinogenesis. 2006 Feb;27(2):232-9 [16141240.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):181-5 [16361076.001]
  • (PMID = 16969348.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / PPAR delta; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2360534
  •  go-up   go-down


92. Ghittoni G, Caturelli E, Viera FT: Intrabile duct metastasis from colonic adenocarcinoma without liver parenchyma involvement: contrast enhanced ultrasonography detection. Abdom Imaging; 2010 Jun;35(3):346-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrabile duct metastasis from colonic adenocarcinoma without liver parenchyma involvement: contrast enhanced ultrasonography detection.
  • It is well-known that biliary duct invasion with intraluminal growth is one of the developmental patterns of primary liver tumors, and macroscopic intrabiliary growth of liver metastases in colorectal cancer is found with high frequency.
  • We describe the first recorded case of a metastasis from colorectal cancer involving solely the common hepatic biliary duct, without invasion of contiguous liver parenchyma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Hepatic Duct, Common / pathology. Ultrasonography, Doppler, Color

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294464.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Mohandas SK, Mazarello F, Bisset R: Right gluteal abscess: an unusual presentation of perforated caecal adenocarcinoma. J Gastrointest Cancer; 2010 Dec;41(4):285-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right gluteal abscess: an unusual presentation of perforated caecal adenocarcinoma.
  • INTRODUCTION: Colonic cancer presenting as a remote abscess in the gluteal region, abdominal wall, retroperitoneal region, groin or thigh is rare.
  • DISCUSSION: In the differential diagnosis of gluteal/ upper thigh abscess the rare possibility of colonic cancer perforation as a cause should be considered.
  • [MeSH-major] Abscess / etiology. Adenocarcinoma / complications. Buttocks / pathology. Cecal Neoplasms / complications. Intestinal Perforation / etiology

  • MedlinePlus Health Information. consumer health - Abscess.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):242-7 [10439171.001]
  • [Cites] Am J Surg. 1996 Sep;172(3):236-8 [8862074.001]
  • [Cites] Surgery. 2000 Apr;127(4):370-6 [10776426.001]
  • [Cites] Acta Med Okayama. 2005 Dec;59(6):281-3 [16418772.001]
  • [Cites] J Comput Assist Tomogr. 1981 Feb;5(1):34-8 [7240495.001]
  • [Cites] Gastrointest Radiol. 1983;8(2):177-81 [6852435.001]
  • [Cites] Dis Colon Rectum. 1986 Nov;29(11):694-8 [3769683.001]
  • [Cites] Ann Surg. 1934 Feb;99(2):246-50 [17867131.001]
  • [Cites] Arch Surg. 1981 Apr;116(4):381-4 [7212996.001]
  • [Cites] Ann Surg. 1974 Nov;180(5):734-40 [4423043.001]
  • [Cites] J Gastroenterol. 2001 Sep;36(9):623-8 [11578067.001]
  • [Cites] Surg Oncol. 2006 Aug;15(2):91-6 [17049848.001]
  • [Cites] N Engl J Med. 1958 Jan 30;258(5):201-7 [13504445.001]
  • [Cites] J Accid Emerg Med. 1999 Jul;16(4):302-3 [10417949.001]
  • [Cites] J R Soc Promot Health. 1999 Dec;119(4):264-7 [10673851.001]
  • [Cites] Can J Surg. 1970 Jan;13(1):9-12 [5414335.001]
  • [Cites] Surg Gynecol Obstet. 1966 Dec;123(6):1212-8 [5953951.001]
  • [Cites] Indian J Gastroenterol. 2004 Jul-Aug;23(4):151-2 [15333978.001]
  • (PMID = 20480260.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Peschaud F, Benoist S, Julié C, Beauchet A, Penna C, Rougier P, Nordlinger B: The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg; 2008 Dec;248(6):1067-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer.
  • OBJECTIVE: The aim of the study was to evaluate the prognostic value of the ratio of metastatic to examined lymph nodes (LNR) in patients with rectal cancer.
  • SUMMARY BACKGROUND DATA: Lymph nodes ratio (LNR) has been shown to have prognostic value in patients with colon cancer.
  • The impact of LNR on disease-free and overall survival in patients with rectal cancer is unknown.
  • PATIENTS AND METHODS: From 1998 to 2004, 307 patients underwent rectal resection for adenocarcinoma.
  • CONCLUSIONS: LNR is the most significant prognostic factor for both overall and disease-free survival in patients with rectal cancer, even in patients with fewer than 12 lymph nodes examined.
  • [MeSH-major] Adenocarcinoma / pathology. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg. 2009 Apr;249(4):701.. Frederique, Peschaud [corrected to Peschaud, Frederique]; Stephane, Benoist [corrected to Benoist, Stephane]; Catherine, Julié [corrected to Julié, Catherine]; Alain, Beauchet [corrected to Beauchet, Alain]; Christophe, Penna [corrected to Penna, Christophe]; Philippe, Rougier [corrected to Rougier, Philippe]
  • (PMID = 19092352.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Sugiura T, Nagino M, Oda K, Ebata T, Nishio H, Arai T, Nimura Y: Hepatectomy for colorectal liver metastases with macroscopic intrabiliary tumor growth. World J Surg; 2006 Oct;30(10):1902-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / surgery. Bile Duct Neoplasms / secondary. Bile Ducts, Intrahepatic / pathology. Colorectal Neoplasms / surgery. Hepatectomy / methods. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Mar;15(3):938-46 [9060531.001]
  • [Cites] Radiology. 1997 Oct;205(1):81-5 [9314966.001]
  • [Cites] Surgery. 1986 Aug;100(2):278-84 [3526605.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):847-51 [8756838.001]
  • [Cites] Surgery. 2001 Jun;129(6):692-8 [11391367.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):155-62 [10982608.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1136-40 [9278662.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(1):23-9 [10436234.001]
  • [Cites] Surgery. 1999 Nov;126(5):829-34 [10568181.001]
  • [Cites] Br J Radiol. 2002 Jun;75(894):497-501 [12124235.001]
  • [Cites] Jpn J Clin Oncol. 1997 Feb;27(1):18-21 [9070335.001]
  • [Cites] Surg Endosc. 1988;2(4):213-9 [3242144.001]
  • [Cites] Endoscopy. 1998 Feb;30(2):182-8 [9592660.001]
  • [Cites] Hepatology. 2000 Jan;31(1):12-7 [10613721.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1030-6 [9298879.001]
  • [Cites] Am J Surg. 2001 Feb;181(2):153-9 [11425058.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1105-12 [2045852.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1032-5 [8402060.001]
  • [Cites] World J Surg. 1998 Mar;22(3):268-76; discussion 276-7 [9494419.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):74-8 [7826164.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] Surgery. 1994 Jun;115(6):674-7 [8197557.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):797-801 [1873704.001]
  • [Cites] Arch Surg. 1997 May;132(5):505-10; discussion 511 [9161393.001]
  • [Cites] Hepatogastroenterology. 1992 Aug;39(4):296-300 [1427569.001]
  • (PMID = 16983470.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS: Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol; 2009 Dec;219(4):435-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Somatic KRAS mutation is an early well-known event in colorectal carcinogenesis but a complete understanding of RAS function and dysfunction in colorectal cancer is still to come.
  • Our aim was to study the incidence of KRAS mutation; KRAS splice variants: KRAS4A and KRAS4B; and their relationships with various clinico-pathological characteristics in colorectal cancer (CRC).In this study, 285 CRC cases were analysed for KRAS mutation by direct DNA sequencing followed by immunohistochemical analysis after validation with real-time PCR assay, to study the protein expression of KRAS4A and -4B isoforms.
  • KRAS4A overexpression was significantly associated with left colon, histology subtype of adenocarcinoma, p27kip1, and cleaved caspase3 expression.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adult. Base Sequence. DNA Mutational Analysis / methods. Female. Follow-Up Studies. Humans. Intestinal Mucosa / metabolism. Male. Microsatellite Instability. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Prognosis. Protein Isoforms / genetics. Protein Isoforms / metabolism. Survival Analysis. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824059.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


97. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G: Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol; 2007 Aug;20(8):843-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging.
  • We investigated the impact of these metastatic deposits in the pericolic fat in a series of 228 patients with advanced colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491597.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Staiger J, Lueben MJ, Berrigan D, Malik R, Perkins SN, Hursting SD, Johnson PF: C/EBPbeta regulates body composition, energy balance-related hormones and tumor growth. Carcinogenesis; 2009 May;30(5):832-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of obesity, an established epidemiologic risk factor for many chronic diseases including cancer, has been steadily increasing in the US over several decades.
  • The mechanisms used to regulate energy balance and adiposity and the relationship of these factors to cancer are not completely understood.
  • Moreover, colon adenocarcinoma cells displayed reduced tumorigenic potential when transplanted into C/EBPbeta-deficient animals, especially males.
  • Thus, C/EBPbeta contributes to endocrine expression of IGF-1, leptin and insulin, which modulate energy balance and can contribute to cancer progression by creating a favorable environment for tumor cell proliferation and survival.

  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Nutr. 2001 Sep;74(3):295-301 [11522551.001]
  • [Cites] Growth Horm IGF Res. 2001 Aug;11(4):213-9 [11735236.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):207-12 [11756662.001]
  • [Cites] Pituitary. 2001 Jan-Apr;4(1-2):63-70 [11824509.001]
  • [Cites] Growth Horm IGF Res. 2001 Dec;11(6):339-45 [11914021.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15261-70 [11825899.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):817-22 [12016155.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):298-302 [12067807.001]
  • [Cites] Biochem J. 2002 Aug 1;365(Pt 3):561-75 [12006103.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):565-74 [12217794.001]
  • [Cites] Oncology. 2002;63(4):317-32 [12417786.001]
  • [Cites] Breast Cancer Res. 2002;4(6):231-9 [12473169.001]
  • [Cites] Annu Rev Med. 2003;54:131-52 [12525670.001]
  • [Cites] J Urol. 2003 Feb;169(2):714-7 [12544349.001]
  • [Cites] J Urol. 2003 Apr;169(4):1308-11 [12629349.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1752-5 [12702556.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4384-8 [12907608.001]
  • [Cites] Int J Cancer. 2004 Mar10;109(1):149-52 [14735482.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3238-50 [15060147.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4325-31 [15240518.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Obes Res. 2004 Sep;12(9):1481-91 [15483213.001]
  • [Cites] Cancer Res. 1975 Sep;35(9):2434-9 [1149045.001]
  • [Cites] Diabetologia. 1978 Mar;14(3):141-8 [350680.001]
  • [Cites] Endocrinology. 1989 Mar;124(3):1247-53 [2645113.001]
  • [Cites] Endocrinology. 1991 Jun;128(6):2895-900 [1645254.001]
  • [Cites] Genes Dev. 1991 Sep;5(9):1538-52 [1840554.001]
  • [Cites] Genomics. 1991 Dec;11(4):1054-62 [1686014.001]
  • [Cites] Genes Dev. 1992 Apr;6(4):533-44 [1373117.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4874-8 [1594587.001]
  • [Cites] Endocrinology. 1992 Jun;130(6):3608-16 [1597158.001]
  • [Cites] Immunol Rev. 1992 Jun;127:25-50 [1380488.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4848-50 [8069850.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] Ann Intern Med. 1995 Jan 1;122(1):54-9 [7619109.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):249-52 [7812953.001]
  • [Cites] Genes Dev. 1995 Jan 15;9(2):168-81 [7531665.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):873-7 [8570651.001]
  • [Cites] Nat Genet. 1996 Mar;12(3):318-20 [8589726.001]
  • [Cites] Endocrinology. 1996 May;137(5):1764-74 [8612513.001]
  • [Cites] Diabetes. 1996 Jul;45(7):984-7 [8666153.001]
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):154-61 [8995241.001]
  • [Cites] J Clin Invest. 1997 Feb 1;99(3):391-5 [9022071.001]
  • [Cites] Diabetes. 1997 Mar;46(3):342-7 [9032087.001]
  • [Cites] Int J Obes Relat Metab Disord. 1997 Apr;21(4):255-60 [9130020.001]
  • [Cites] Genes Dev. 1997 Sep 1;11(17):2153-62 [9303532.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28349-59 [9353292.001]
  • [Cites] J Biol Chem. 1997 Dec 12;272(50):31793-800 [9395525.001]
  • [Cites] EMBO J. 1997 Dec 15;16(24):7432-43 [9405372.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):1013-22 [9492033.001]
  • [Cites] Clin Chem. 1998 Mar;44(3):565-70 [9510863.001]
  • [Cites] Science. 1998 May 29;280(5368):1378-83 [9603721.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10908-13 [9724803.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29279-82 [9792624.001]
  • [Cites] Circ Res. 1998 Nov 16;83(10):1059-66 [9815153.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10609-17 [10187857.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):679-85 [15681294.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2592-601 [15805255.001]
  • [Cites] In Vivo. 2005 Jul-Aug;19(4):667-74 [15999532.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26751-9 [15899886.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1646-52 [16030096.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):407-20 [15886048.001]
  • [Cites] EMBO J. 2005 Sep 21;24(18):3301-12 [16107878.001]
  • [Cites] Oncogene. 2006 Feb 23;25(8):1272-6 [16205634.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1447-53 [16533767.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] Cell Cycle. 2006 May;5(9):953-7 [16687924.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5611-4 [17020962.001]
  • [Cites] Endocrinology. 2006 Dec;147(12):5826-34 [16959846.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):1-12 [17237261.001]
  • [Cites] J Biol Chem. 2007 May 25;282(21):15717-29 [17387171.001]
  • [Cites] Science. 2007 Jul 6;317(5834):121-4 [17615358.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Aug;7(5):484-91 [17691908.001]
  • [Cites] Brain Res. 1999 Nov 27;848(1-2):114-23 [10612703.001]
  • [Cites] J Neurosci. 2000 Aug 1;20(15):5703-8 [10908609.001]
  • [Cites] Obes Res. 2000 Aug;8(5):392-8 [10968731.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2122-5 [11000114.001]
  • [Cites] Prostate. 2001 Jan 1;46(1):62-7 [11170133.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15354-61 [11278589.001]
  • (PMID = 19056928.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-beta; 0 / Insulin; 0 / Leptin; 142662-43-9 / CCAAT-Enhancer-Binding Protein-delta; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC2675647
  •  go-up   go-down


99. Safaee A, Moghimi-Dehkordi B, Fatemi SR, Ghiasi S, Nemati-Malek F, Zali MR: Characteristics of colorectal mucinous adenocarcinoma in Iran. Asian Pac J Cancer Prev; 2010;11(5):1373-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of colorectal mucinous adenocarcinoma in Iran.
  • AIMS AND BACKGROUND: Mucinous adenocarcinoma (MA) colorectal cancer accounts for 10 to 15% of colorectal carcinoma.
  • METHODS: Between January 2002 and March 2008, Of the 1283 colorectal cancer patients, 110 patients were considered to have mucinous tumors according to pathology report.
  • Patients evaluated on the basis of sex, age, location of tumor, stage, differentiation of tumor and family history of cancer.
  • 34.5% of patients had a family history of colorectal cancer in their first-degree relatives.
  • Most tumors were presented in right colon.
  • CONCLUSION: Our suggests that genetic factors may be play an important role in the development of this disease in our country and screening programs, especially genetic screening programs, should be considered as a main measure for prevention and control of colorectal cancer in Iran.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21198295.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


100. Sun JH, Das KK, Amenta PS, Yokota K, Watari J, Sato T, Kohgo Y, Das KM: Preferential expression of cyclooxygenase-2 in colonic-phenotype of gastric intestinal metaplasia: association with helicobacter pylori and gastric carcinoma. J Clin Gastroenterol; 2006 Feb;40(2):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential expression of cyclooxygenase-2 in colonic-phenotype of gastric intestinal metaplasia: association with helicobacter pylori and gastric carcinoma.
  • However, GIM phenotype associated with HP infection and gastric cancer is unclear.
  • METHODS: We evaluated cellular phenotype and COX-2 expression in the GIM from HP-positive and -negative patients from Japan in the absence of gastric cancer (n = 31) by using a colon epithelium specific monoclonal antibody (mAb Das-1) and anti-COX-2 antibody.
  • COX-2 expression was also examined in patients with gastric cancer (n = 34), both in the cancer and in the GIM areas away from the cancer field.
  • In the cancer group, COX-2 expression was localized both in the cancer area (94%) and in the GIM (82%) away from the cancer.
  • CONCLUSION: HP infection is highly associated with the development of colonic-phenotype of GIM, and about half of them expressed COX-2.
  • COX-2 expression was frequent in both gastric cancer and the GIM adjacent to the cancer.
  • The results suggest that the presence of mAb Das-1 and COX-2 reactivity in the GIM identify the subgroup of patients who may be at risk for gastric cancer and may need close surveillance.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclooxygenase 2 / metabolism. Gastric Mucosa / metabolism. Helicobacter Infections / metabolism. Helicobacter pylori / metabolism. Metaplasia / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16394872.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / R01 47673
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / DAS-1 protein, human; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down






Advertisement